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ABSTRACT
Parkinson’s disease is a common neurodegenerative disorder resulting from
progressive loss of dopaminergic neurons in the substantia nigra pars compacta region of
the midbrain. Mitochondrial dysfunction and oxidative stress are major contributors to
this disease.

Currently there is no treatment to halt the progression of Parkinson’s

disease; there are only drugs for symptomatic relief. Previously, prophylactic treatment
with a water-soluble formulation of coenzyme Q10 was shown to reduce the loss of
dopaminergic neurons in the substantia nigra and ameliorate symptoms in a paraquatinduced rat model of Parkinson’s disease. In this work, delivery of CoQ10 by the watersoluble formulation shows increased bioavailability in various rat tissues, including the
brain. Also observed is a decrease in the loss of dopaminergic neurons in the substantia
nigra by therapeutic water-soluble CoQ10 supplementation in a rat model. Hence, this
formulation of CoQ10 may be used to slow or halt the progression of Parkinson’s disease.
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CHAPTER I
INTRODUCTION
1.1. Parkinson’s Disease
In 1817, James Parkinson was the first to describe one of the most common
neurodegenerative disorders, the “shaking palsy” known today as Parkinson’s disease
(Parkinson, (1817) 2002). It is the second most common neurodegenerative disease,
behind Alzheimer’s disease, and affects over 5 million people worldwide (Michael J. Fox
Foundation for Parkinson’s Research, MichaelJFox.org).
Parkinson’s disease (PD) is characterized by the progressive loss of dopamine
producing neurons, primarily in the substantia nigra pars compacta (SNpc) region of the
midbrain. The loss of these neurons contributes to the symptoms commonly associated
with PD: bradykinesia, resting tremors, rigidity, loss of balance, stooped posture and
shuffling gait, which usually do not develop until more than 60% of the dopaminergic
(DA) neurons have already been lost (Jankovic, 2008). One of the main hallmarks of PD
is the presence of cytoplasmic Lewy bodies, composed of α-synuclein protein aggregates
in the surviving dopaminergic neurons (Lozano & Kalia, 2005; Wakabayashi et al.,
2007). They can also be found in other areas of the brain such as the cortex and basal
forebrain (Braak et al., 1995).
Currently there are no treatments available to slow or halt the progression of PD.
There are some drugs such as levodopa that temporarily ameliorate symptoms, but these
drugs cannot sustain aid after long-term use. Therefore, it is of great importance to
develop a therapy that will help patients diagnosed with PD to live full and almost normal
lives.
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1.2. Synthesis, Release and Metabolism of Dopamine
Dopamine is a neurotransmitter required for a variety of biological functions
including: voluntary movement, motivation, behaviour and cognition, punishment and
reward, sleep, mood, attention, working memory and learning. It also acts as both a
positive inotrope and chronotrope that increases heart rate by strengthening its muscular
contractions (Howard, 2008).
Dopamine is classified as a catecholamine due to its derivation from the amino
acid tyrosine. Tyrosine is converted into L-3,4-dihydroxylphenylalanine (L-DOPA) by
the enzyme tyrosine hydroxylase (TH) and then to dopamine by DOPA decarboxylase
(Figure 1). Dopamine can also be further processed into norepinephrine and epinephrine,

Figure 1: Dopamine synthesis. The catecholamine, dopamine, is derived from the
amino acid tyrosine using the rate-limiting enzyme tyrosine hydroxylase and L-Dopa
carboxylase.
2

other neurotransmitters involved with the fight-or-flight response. The enzymes, tyrosine
hydroxylase and DOPA decarboxylase, are found in the soma of neurons where they are
transported to the axon to synthesize dopamine. Once it is synthesized, transporting
vesicles called vesicular monoamine transporters (VMAT), transport dopamine through
the synaptic cleft to the target neuron. The action of the neurotransmitter is terminated by
either uptake back into nerve terminals or uptake from nearby glial cells by Na+dependent dopamine transporters (DAT) (Moron et al., 2002, Figure 2).
The enzymes required to degrade dopamine into homovanillic acid are
monoamine oxidase and catechol O-methyltransferase, which both glial cells and neurons
possess (Dziedzicka-Wasylewska, 2004; Joh & Hwang, 1987). Homovanillic acid is then
excreted in urine.

Figure 2: Neurotransmitting dopamine. Signally neurons from the substantia nigra
pars compacta to the striatum transport the neurotransmitter dopamine from vesicular
monoamine transporters to D1 receptors.
3

1.3. The Nigrostriatal Pathway
The majority of dopamine in the brain (80%) is produced in the substantia nigra
and ventral tegmental area (VTA, Carlsson, 1959), and additionally by the arcuate
nucleus of the hypothalamus. Dopamine originating in these three regions is involved in
four main pathways: mesocortical, mesolimbic, tuberoinfundibular and nigrostriatal
(Figure 3).

Figure 3: Dopaminergic pathways. Sources and projections of three main dopamine
pathways in the human brain.
The nigrostriatal pathway is the pathway most associated with Parkinson’s disease
because it is mainly involved with voluntary movement and cognitive function, both of
which are compromised in PD due to the loss of dopaminergic neurons. The nigrostriatal
pathway is courses through the cortex, thalamus and basal ganglia. The basal ganglia are
a group of nuclei consisting of the striatum (further containing the putamen and caudate
nucleus), the globus pallidus: pars intera and pars externa, the subthalamic nucleus and
the substantia nigra (Figure 4).

4

Figure 4: Nigrostriatal pathway. Dopamine is projected from the substantia nigra pars
compacta to the putamen and caudate nucleus.

The basal ganglia circuitry is considered a neuronal loop that receives cortical
input and transmits back to the motor cortex via the thalamus. The neurons in the basal
ganglia modulate their own activity in anticipation of movement, sometimes up to several
seconds before initiation, as well as during voluntary movements (Purves et al., 2008).
The circuitry of the basal ganglia can be further subdivided into the direct
pathway, and indirect pathway (Figure 5). In the direct pathway the striatum receives
dopaminergic transmission from the substantia nigra pars compacta through the D1
receptor; this in turn creates an inhibitory signal to the globus pallidus pars interna that

5

further inhibits projections to the thalamus.

This allows the thalamus to give an

excitatory signal to the motor cortex where it can reach the muscles and initiate
movement. Overall, the direct pathway is excitatory and is modulated by the substantia
nigra pars compacta and dopamine receptor, D1.
Alternatively, the indirect pathway involves an inhibitory projection to the
striatum from the substantia nigra pars compacta through D2 receptors. This inhibitory
pathway follows the striatum to the globus pallidus pars externa to the subthalamic
nucleus. The subthalamic nucleus sends an excitatory signal to the globus pallidus pars
interna that inhibits the excitatory projects of the thalamus to the cortex (Figure 5).
Overall, the indirect pathway is inhibitory and modulated through the D2 dopamine.

Figure 5: Basal ganglia circuitry. Neuronal loop modulated by the substantia nigra pars
compacta through D1 and D2 receptors leading to either the direct or indirect pathway.
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The indirect pathway influences the direct pathway in a way that leads to opposite,
yet synergistic effects. Increasing levels of dopamine from the direct pathway decreases
the sensitivity of the indirect pathway, amplifying the excitatory signal. The opposite is
true in situations with decreased levels of dopamine, which increases sensitivity and
amplifies the inhibitory signal from the direct pathway. In Parkinson’s disease, loss of
dopamine transmission to the basal ganglia is high, contributing to the characteristic
symptoms, such as difficulty initiating movement.

Post-mortem studies of those

diagnosed with PD have shown a decrease of dopamine in the substantia nigra, globus
pallidus, putamen and caudate nucleus, as well as a decrease in dopamingeric neuronal
fibres in the striatum (Hornykiewicz, 2006).

1.4. Etiology of Parkinson’s Disease
The average age of onset of Parkinson’s disease is 60 years; however, the
occurrence of early onset is on the rise and prevalent in approximately 4% of people
diagnosed with PD (Parkinson’s Disease Foundation, PDF.org). Interestingly, males are
2.5 times more likely to develop this disease than women. This is believed to be due to
the neuroprotective effects of estrogen in the SN from higher levels of glutaredoxin that is
expressed through estrogen receptor signaling (Kenchappa et al., 2004).
The cause of PD is unknown, but it is believed that both genetic and
environmental factors, especially in combination contribute to the development of the
disease (Terzioglu & Galter, 2008). A study using monozygotic and dizygotic twins in
the 1990s determined that PD is not hereditary, although early onset PD has been linked
to genetic factors (Tanner et al., 1999).

The natural aging process is another factor in

developing PD due to the fact that most brain neurons are post-mitotic, and oxidative
7

stress increases with age (Beal, 2003; Bishop et al., 2010; Hindle, 2010). Normal brains
lose 4.7% to 6% of neurons between the ages of 50 and 90 (Gibb & Lees, 1991). Since
the average life expectancy is increasing, so is the prevalence of PD.
Sporadic incidences of PD account for more than 95% of PD cases and may be
influenced by environmental factors, such as exposure to herbicides and pesticides.
People who work in agriculture and are exposed to these toxins have a 2.5 times increased
risk of developing PD (Tanner et al., 2011). On the other hand, genetic factors attribute
to less than 5% of incidences of PD. To date, several genes that acquire mutations have
been linked to the disease: PARK2 (Parkin), PARK6 (PTEN-induced kinase 1), αsynuclein, leucine-rich repeat kinase 2 (LRRK2) and DJ-1. What is most interesting is
that several of these genes affect mitochondrial function, whose involvement in
Parkinson’s disease will be described in detail (Abou-Sleiman, Muquit & Wood, 2006).
Currently, there are no genetic or animal models for PD that can replicate all the
key features of the disease: motor deficits, dopaminergic neuronal cell loss in the SN, loss
of dopaminergic fibers in the striatum and the presence of Lewy bodies. In fact, most
mutations associated with PD simply increase predisposition to the disease and do not
lead to the development of the symptoms directly. Therefore, genetic models are better
suited for increasing susceptibility to PD pathology through means of inducing oxidative
stress, protein aggregation, and interfering with dopamine neurotransmission. However,
the models that have been established greatly contribute to our understanding of the
disease and enhance the opportunity of discovering a cure.
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1.5. Genetic Causes of Parkinson’s Disease
There have been many discoveries of genes associated with or leading to
Parkinson’s disease. The following table is a summary of the genes discovered to date
(Table 1).

Table 1: Parkinsonism genetics. Genes leading to Parkinsonism and their pathology
(modified from Hardy, 2010).
Locus
Genes
Dominant
PARK1/4 α-Synuclein
PARK8

LRRK2

Recessive
PARK2
Parkin

PARK6

PINK1

PARK7

DJ-1

PARK9

ATP13A2

PARK14

PLA2G6

Clinical Features

Pathology

Typical PD but can sometimes
have a dementia presentation
Typical PD

Lewy bodies

Very slowly progressive early
onset disease usually with
sleep benefit
Usually very slowly
progressive early onset disease
usually with sleep benefit
Little data, but seems similar
to parkin
Aggressive and complex
parkinsonism with many
additional features
Aggressive and complex
Parkinsonism with many
additional features

Usually not Lewy bodies

Usually Lewy bodies:
sometime tangles,
sometimes neither

One case with Lewy
bodies
Not known
Not known

Lewy bodies

1.5.1. Alpha-synuclein
Alpha-synuclein is a protein expressed in the central nervous system whose actual
function is not clearly understood, but may be linked to coordinating nuclear and synaptic
events. In regards to Parkinson’s disease, α-synuclein is the main protein that aggregates
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in Lewy bodies in both sporadic and while rare, familial incidences of PD, due to genetic
mutations (Stoica et al., 2012). In a spontaneously inherited autosomal recessive rat
model of Parkinson’s disease, it was discovered that α-synuclein was largely increased in
the midbrain along with decreased levels of DA in the striatum. The high accumulation
of α-synuclein in the midbrain is believed to lead to the deterioration of nerve terminals,
synapses and dendrites that in turn debilitate the transmission of DA (Stoica et al., 2012).
It is still unclear whether α-synuclein is neuroprotective or neurotoxic under certain
circumstances, ranging from environmental toxic exposure to genetic mutations.

1.5.2. PARK Gene Family
Mutations in the PARK8 gene coding for the leucine-rich repeat kinase 2 protein
(LRRK2), causes familial PD (Zimpritch et al., 2004).

There have been up to six

mutations detected in this gene that can lead to Parkinsonian symptoms including
dopaminergic cell death, Lewy bodies, and dementia. The most frequently occurring
G2019S mutation is linked to both sporadic and familial PD (Gilks et al., 2005). It has
been shown to cause decreased striatal dopamine transmission, a loss of dopaminergic
neurons, and abnormalities in both mitochondrial function and autophagy in a transgenic
mouse model (Li X et al., 2010; Ramonet et al., 2011). While the G2019S mutation does
not show any motor deficits, the R1441G mutation leads to reduced mobility (comparable
to bradykinesia), as well as tau protein aggregation in transgenic (BAC) mice (Li Y et al.,
2009).
Parkin is an ubiquitin protein ligase expressed by the PARK2 gene that is most
widely known, when mutated, to cause early onset Parkinson’s disease. Those affected
with a Parkin mutation usually develop the symptoms of PD, with the exception of Lewy
10

body formation, before the age of 40 (early onset) (Poorkaj et al., 2005). Staggering
statistics estimate that almost 50% of familial PD and 18% of sporadic PD are due to
Parkin mutations (Clark et al., 2006).
PTEN induced kinase 1 (PINK1) protein is expressed by the PARK6 gene whose
mutations cause autosomal recessive and early onset PD (Valente et al., 2004). PINK1 is
found in the mitochondria and associated with phosphorylation involved in
morphogenesis and fission, as well as mitochondrial autophagy (Yan et al., 2012). In cell
culture models, knockdown of PINK1 causes mitochondrial and proteasome dysfunction
and alpha-synuclein aggregation (Liu et al., 2009).
The PARK7 gene mutation corresponds to DJ-1 protein misfolding or loss of
function at its highly conserved cysteine residue (L166P) (Wilson et al., 2003). DJ-1 is
found in the cytoplasm of cells, and in the event of oxidative stress, is translocated to the
mitochondria (Canet-Aviles et al., 2004). There it can perform anti-oxidative activities
by oxidizing itself; however, when the L166P cysteine is mutated it cannot homodimerize
and loses its function (Takahashi-Niki et al., 2004). The protein is known to help reduce
oxidative stress by scavenging H2O2, inhibiting α-synuclein aggregation and regulating
other pro-survival genes (Junn et al., 2009). The DJ-1 mutation is associated with early
onset PD; however it is a rare occurance and does not show loss of dopaminergic neurons
on its own (Bonifati et al., 2003; Yamaguchi & Shen, 2007). Current studies are using
DJ-1 knockout animals combined with environmental toxins, such as 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) (Kim et al., 2005), and paraquat to induce
Parkinsonism symptoms is a more realistic model of PD. DJ-1 deficient mice challenged
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with MPTP have an increase in both oxidative stress and dopaminergic neuronal cell
death (Bohlen & HO, 2005).

1.6. Toxin and Environmental Causes of Parkinson’s Disease
1.6.1. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
In vivo models of idiopathic PD have always been difficult to establish. However,
in the 1980s a major breakthrough was made when a group of heroine addicts displayed
symptoms of PD at a young age. It was discovered that a by-product, 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP, Figure 6) of the synthetic heroine they were injecting
intravenously, was the cause of their PD-like symptoms. Post mortem studies revealed
these addicts had a selective loss of SN neurons and Lewy body inclusions (Langston,

Figure 6: Neurotoxins. Structures of neurotoxins: oxydopamine, rotenone, MPTP,
MPP+ and paraquat. All can be involved in the pathogenesis of Parkinson’s disease.
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1983). This compound provided the first model to be used in PD research and was a
gateway to discovering similar toxins that could potentially contribute to PD pathology.
MPTP is a lipophilic, non-toxic compound that can easily cross the blood-brain
barrier. It becomes toxic to neurons when metabolized by astrocytes into 1-methyl-4phenylpyridinium (MPP+, Figure 7) by monoamine oxidase B. MPP+ enters neurons by
DAT, where it accumulates in the DA neurons and inhibits complex I of the
mitochondrial electron transport chain (ETC). This disrupts mitochondrial function and
leads to an increase in ROS, lipid oxidation and protein oxidation in rodent models
(Smeyne & Jackson-Lewis, 2005). MPP+ can also inhibit complex III and IV further
decreasing adenosine triphosphate (ATP) production and increasing oxidative stress
(Mizuno et al., 1988). When MPTP is converted to MPP+ in the astrocytes, it stimulates
TNF-α, IL-1B, and IL-6 expression leading to inflammation and neuronal cell death
(Teismann et al., 2003; Youdim et al., 2002).
Increased doses of MPTP in mice showed a progressive loss of DA neurons in the
SN as well as decreased DA terminals in the striatum and clear motor deficits (Goldberg
et al., 2011).

These deficits have also been shown in a variety of animal models

including rodents, cats, mini-pigs and non-human primates (Jenner, 2003; Wichmann &
DeLong, 2003; Terzioglu & Galter, 2008).
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MPDP

DAT

Figure 7: MPTP metabolism. MPTP is first converted to MPDP (1-methyl-4-phenyl2,3,-dihydropyridinium) by monoamine oxidase, then spontaneously to MPP+ in
astrocytes. MPP+ enters dopaminergic neurons via DAT and increases oxidative stress
by blocking complex I of the ETC.

1.6.2. Paraquat
The environmental toxin, 1,1′-dimethyl-4,4′-bipyridium (paraquat, PQ) is one of
the most widely used herbicides in the world (Dinis-Oliveira et al., 2008; Frabotta, 2009).
It is structurally similar to the neurotoxin MPP+ with the addition of a methylpyridinium
group (Figure 6). Unlike MPP+, PQ does not use dopamine transporters to enter DA
neurons; instead it enters via diffusion and is then taken up by the mitochondria through
neutral amino acid transporters (Shimizu et al., 2001; McCormack et al., 2003).
Exposure to PQ causes superoxide production that takes place in the
mitochondrial matrix and leads to mitochondrial oxidative damage, lipid oxidation, and
protein peroxidation.

There is controversy whether paraquat is involved directly at

complex I of the mitochondrial ETC or by Bak-dependent mechanisms. If at complex I,
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PQ2+ is reduced by a single electron from NADH and forms the radical cation (PQ⋅+)
(Cocheme & Murphy, 2008).

The radical quickly reacts with oxygen to create a

superoxide radical (O2⋅-), which can then be converted to hydrogen peroxide (H2O2) by
superoxide dismutase leading to oxidative stress (Berry et al., 2010, Figure 8). The other
possibility is that PQ stimulates high levels of pro-apoptotic Bcl-2 family members
through oxidative stress, which induce the intrinsic apoptosis pathway (Qingyan et al.,
2008).

Nonetheless, in animal models, exposure to PQ induces PD-like symptoms

including specific loss of TH positive neurons in the SN (Betarbet et al., 2002; Terzioglu
& Galter, 2008; McCormack et al., 2002; Ossowska, 2006).
Studies from Taiwan and East Texas found that exposure to paraquat increased the
risk of developing PD, especially with more than 20 years of exposure (Liou et al., 1997;

Figure 8: Reduction-oxidation cycling of paraquat. Paraquat blocks complex I of the
ETC by preventing electron transfer from NADH. Instead, PQ receives the electron and
becomes a radical that reacts with oxygen to form a superoxide.
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Dhillon et al., 2008). Another study found exposure at younger ages increased the risk as
well as the early onset of acquiring PD (Costello et al., 2009). Even more recently,
studies show evidence that paraquat and rotenone are linked to PD. Out of 31 pesticides
that were evaluated, rotenone was considered to have the strongest correlation to PD as a
complex I inhibitor and paraquat had the strongest association with PD as an oxidative
stressor (Tanner et al., 2011).
Paraquat has also been associated with histone acetylation, specifically of H3 in
cell culture models.

The inhibition of histone acytltransferase (HAT) activity (via

anacardic acid) protects against apoptotic dopaminergic cell death. It reduces histone
deacetylase activity and may be a key player in the epigenetic changes of PD (Song et al.,
2011). The mechanism of paraquat toxicity has shown to include the up-regulation of a
superoxide-generating enzyme, NADPH oxidase 1 (Nox1). Increased expression of Nox1
by paraquat induces oxidative stress and leads to dopaminergic neuronal loss (Cristovao
et al., 2009).

1.6.3. Rotenone
Rotenone (Figure 6) is a ketone found in the roots and stems of the Lonchocarpus
species of tropical plants and was initially used as a fish poison by native Indians
(Uversky, 2004). Since rotenone is lipophilic, it can cross the blood brain barrier (BBB)
and easily enter the mitochondrial membrane. It has a high affinity for the PSST subunit
of complex I (NADH:ubiquinone reductase) of the ETC (Nicolaou et al., 2000; Schuler &
Casida, 2001). By inhibiting complex I, rotenone increases oxidative stress by ROS
production, protein oxidation, and mitochondrial dysfunction (Kushnareva et al., 2002;
Sherer 2003b).
16

In nature, rotenone can break down very quickly in sunlight, water and soil, with a
half-life ranging between 1 to 3 days (Pesticides News, 2001). Therefore, exposure to
rotenone is not a very likely cause of PD. Conversely, a recent study found that exposure
to rotenone was associated to an increased risk of developing PD (Tanner et al., 2011).
Despite this, rotenone is a good model for studying PD in both cell culture and animal
models.

Rotenone administered intrajugularly, subcutaneously, intraperitoneally by

infusion or chronically, induces a loss of DA neurons (Betarbet, 2000; Sherer, 2003c;
Alam & Schmidt, 2002). Since rotenone does not enter DA neurons through DAT like
MPP+, it penetrates all mitochondria throughout the brain; however, it shows a specific
loss of DA neurons in the SN. Rotenone also induces cytoplasmic inclusions much like
Lewy bodies that contain α-synuclein (Betarbet, 2000; Sherer, 2003).

Furthermore,

rotenone administration gives rise to behavioural deficits similar to PD symptoms such as
bradykinesia, rigidity and postural problems (Betarbet et al., 2000; Sherer et al., 2003c).
The downside to this model is that the severity of neuronal damage is highly variable;
some motor deficits could be due to other factors such as general health problems and
some studies have shown non-DA neuron striatal damage (Hoglinger et al., 2003).

1.6.4. Oxidopamine/6-hydroxydopamine (6-OHDA)
The most widely used and reproducible model of PD uses the neurotoxin 6hydroxydopamine, a hydroxylated derivative of dopamine (Figure 6).

Given that it

cannot cross the blood-brain barrier, it must be injected directly into the brain, usually
into the striatum or SN region. In rodents, dopamine transporters and norepinephrine
transporters (NET) carry the toxin to neurons, where it induces reactive oxygen species
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(ROS) leading to the death of DA neurons (Bove et al., 2005). However, it cannot mimic
the progressive loss of DA neurons (Mercanti et al., 2012). What is novel about this
method is that the animal can provide its own control by injecting unilaterally. DA loss
can be seen only in the ipsilateral hemisphere where the injection was given; the other
hemisphere remains untouched (Blandini et al., 2008, Figure 9).

Figure 9: Tyrosine hydroxylase positive neurons following oxidopamine injections.
When oxidopamine is injected into the brain, a loss of SN and VTA dopaminergic
neurons (darkly coloured) can be seen on the same side as the injection, whereas the other
side of the brain is completely unaffected (Costa et al., 2012).
1.7. Mechanism of Neurodegeneration
Whether the source is genetic, environmental or a combination of the two, the
pathogenesis of Parkinson’s disease has boiled down to a few common mechanisms
involving mitochondrial dysfunction leading to oxidative stress and inflammation.
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1.7.1. Oxidative Stress Leading to Mitochondrial Dysfunction
Oxidative stress exists when there is an imbalance of reactive oxygen species
production and antioxidant activity. Neurons are highly sensitive to oxidative stress
because they depend almost solely on oxidative phosphorylation for energy.
Mitochondria, where this oxidative phosphorylation takes place, are already under high
levels of oxidative stress and therefore any increase in internal or external ROS tips the
balance and leads to mitochondria becoming dysfunctional. This in turn produces more
ROS leading to a damaging and unending cycle (Figure 10).
To combat ROS production, mitochondria use manganese superoxide dismutase,
which converts superoxide radicals to hydrogen peroxide. The hydrogen peroxide is then
further converted by peroxidases into water (Harrison & Hollensworth, 2005). However,
in situations with high levels of oxidative stress, these enzymes are sometimes
inadequate. Likewise, as we age, we become more susceptible to oxidative stress.

Figure 10: Mitochondria under oxidative stress. Unfavorable conditions in the
mitochondria due to environmental toxin exposure lead to a cycle of ROS production.
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1.7.2. Oxidative Stress in Parkinson’s disease
Susceptibility to this disease can be due to genetics, environmental toxins
(including most pesticides and herbicides) or a combination of the two, which can cause
mitochondrial damage, eventually leading to oxidative stress.
Generation of reactive oxygen species at complex I, coined “complex I
syndrome,” in the ETC has been linked to age-associated modifications in the central
nervous system (Harrison et al., 2005; Nobre et al., 2009). Increased levels of oxidized
glutathione (GSSG) with a correlated decrease in reduced glutathione (GSH), oxidized
protein, and increased lipid peroxidation are all common ways of measuring oxidative
stress and the extent of damage caused by it. Lipid peroxidation causes a collapse of
plasma and mitochondrial membranes, releasing cytochrome c and inducing apoptosis.
The brain is most affected by lipid peroxidation because of its high oxidizable lipid and
metal content in comparison with other tissue (Nobre et al., 2009). Chronic exposure to
hydrogen peroxide has been shown to have a protective role by inducing up regulation of
antioxidant enzymes such as catalase and superoxide dismutase (Gomez-Cabrera et al.,
2008). A study that measured oxidized CoQ10 in the cerebrospinal fluid of untreated PD
patients discovered that oxidative damage to mitochondria and mitochondrial DNA may
be involved in the pathogenesis of PD (Isobe et al., 2010).

1.7.3. Neuroinflammation
Neuroinflammation in the midbrain occurs several years before the onset of PD
symptoms (Zinger, 2011).
neuroinflammatory process.

Microglia are modified immune cells involved in the
These microglia are microphages recruited by pro-

inflammatory messengers, cytokines, and chemokines to the area of damaged brain tissue.
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The main job of microglia is to phagocytose damaged neurons, that in turn release toxic
materials and further recruit pro-inflammatory molecules and a damaging cycle begins.
As well, microglia themselves can release pro-inflammatory molecules such as, TNF-α,
ROS, and NOS (Gehrmann, 1995). In healthy brains, there is a balance between the
protective and inflammatory responses, but similar to oxidative stress, any extra influence
tips the balance.
Out of all the other brain areas, the substantia nigra contains the highest amount of
microglia (McGeer, 1988).

Microglia are believed to play a significant role in the

initiation and progression of PD. An increase in activated microglia in the midbrain has
been shown in positron emission tomography (PET) scans of PD patients, especially in
the early stages of the disease (Ouchi, 2005). Other post-mortem studies have found that
an increase in activated microglia was initiated by up-regulation of α-synuclein. The
microglia activation was found to be early in the diagnosis and lasted throughout the
disease (Sanchez-Guajardo, 2010).

1.8. Antioxidants as Possible Therapeutic Agents for Parkinson’s Disease
Antioxidants are reducing agents that inhibit the oxidation of molecules into
becoming free radicals. The role of antioxidants in maintaining redox balance is well
known and although they are able to alleviate the effects of oxidative stress, nothing has
been discovered that can stop the neurodegeneration process associated with oxidative
stress.
Recent studies for the treatment of PD have been directed towards anti-oxidative
agents that target and stabilize the mitochondria (Muller et al., 2010). Some of these
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treatments include: glutathione, curcumin, Vitamin E, Vitamin C, Vitamin A,
peroxidases, ubiquinol (coenzyme Q, Table 2). Some of these will be explained in
greater detail as they pertain to the therapeutic treatment of PD in a rat model.
Table 2: Effects of antioxidants on neurodegenerative diseases. Common antioxidant
compounds with antioxidative properties have shown to play a role in reducing oxidative
stress in Parkinson’s disease, Alzheimer’s disease and stroke (Facecchia et al., 2011).

1.8.1. Vitamin E
Tocopherol (Vitamin E) is a fat-soluble alcohol needed for the stabilization of cell
membranes. It is found in such foods as egg yolks, and vegetables and can also be taken
as a health supplement, where it has been found to be safe at high doses (Hathcock,
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2005). Vitamin E can easily cross the BBB and acts as an antioxidant for lipid radicals
produced from lipid peroxidation (Halliwell & Gutteridge, 1989).

It can also aid

glutathione in reducing lipid peroxidation and oxidative stress by maintaining its nonradical antioxidative characteristics through reduction (Van Haaften et al., 2003; Gupta et
al., 2011, Figure 11).

Studies have shown that vitamin E is effective in decreasing

oxidative stress, increasing life span, and improving brain mitochondria efficiency,
specifically in the hippocampus and frontal cortex of aging rodent brains (Vatassery et
al., 2004; Navarro et al., 2010).

Figure 11: GSH and Vitamin E interaction. Vitamin E (α-tocopherol) reduces lipid
peroxidation and in turn Vitamin E radicals are restored to their reduced state by GSH
(Van Haaften et al., 2003).

1.8.2. Coenzyme Q10 (CoQ10)
Coenzyme Q10 is an important hydrophobic compound found consistently
throughout all membranes, especially in the mitochondrial membrane. It is the only
endogenously biosynthesized lipid-soluble antioxidant, important for maintaining both
lipid and mitochondrial membranes (Noack et al., 1994; Forsmark-Andree et al., 1997;
Bentinger et al., 2007).

CoQ10 has four major functions: redox carrier, antioxidant,

uncoupling protein activator and has influence on the permeability transition pore.
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The primary role of CoQ10 in regards to redox reactions involving ATP production
is to shuttle electrons from complex I and II to complex III of the mitochondrial ETC. It
does this by binding to complex I at the iron center containing PSST subunit site where it
is reduced from its fully oxidized ubiquinone form to its ubisemiquinone semiquinone
form, which it can then accept another electron to become fully reduced ubiquinol
(Schuler et al., 1999; Bentinger et al., 2007, Figure 12).

Figure 12: Involvement of CoQ10 in the electron transport chain. CoQ10 shuttles
electrons from complex I, and complex II to complex III of the electron transport chain
(Liu & Schubert, 2009).

As mentioned previously, complex I of the ETC is a major source of ROS
(Murphy, 2009). Since CoQ10 is found in high concentrations in the mitochondrial
membrane around complex I, it is a good candidate for treatment of neurodegerative
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diseases that are the result of mitochondrial oxidative stress. However, due to its highly
hydrophobic nature, CoQ10 cannot be used in cell culture media. Therefore, very little
has been published regarding in vitro CoQ10 studies.
In vivo studies on the other hand have shown that CoQ10 can provide
neuroprotection to DA neurons in the SN, striatal dopamine terminals, DA axons and
reduce α-synuclein aggregation in an MPTP mouse model, including chronically
administered MPTP and aged mice (Beal et al., 1998; Cleren et al., 2008). This has also
been shown in primates (Horvath et al., 2003). CoQ10 unlike other antioxidants can
inhibit the initiation of protein and lipid oxidation instead of combating it (Bentinger et
al., 2007).

1.8.3. Water-soluble Coenzyme Q10
Due to the lack of in vitro studies, and low bioavailability associated with CoQ10,
a new water-soluble formulation was developed (NRC, Ottawa). CoQ10, α-tocopherol,
and polyethyleneglycol were combined to form a nanomicelle in aqueous solutions
(Figure 13).
Firstly, polyoxyethanyl α-tocopheryl sebacate acid (PTS) is synthesized by
conjugating polyethylene glycol 600 to α-tocopherol via bi-functional sebacic acid
(Sigma-Aldrich, St. Louis, MO) as previously described (Borowy-Borowski et al., 2004).
Next, CoQ10 is dissolved in a solution with PTS forming a non-covalent complex and
then a ‘nanomicelle.’ The important 2:1 ratio of PTS to CoQ10 is imperative to its
function (Sikorska et al. 2003, Borowy-Borowski et al. 2004). After oral administration,
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it is cleaved by non-specific esterases and PTS is hydrolyzed to Vitamin E. This allows
for aqueous delivery of CoQ10 and Vitamin E.

Non-specific esterase

Vitamin E

n

Sebacic acid

PEG-600

Figure 13: Water-soluble formulation of coenzyme Q10. Nanomicelles form around
hydrophobic CoQ10 in solution to allow for aqueous delivery of the compound
(Zymes LLC).
FigureThis
13: water-soluble
Water-solubleformulation
formulation
coenzyme
Q10.10Nanomicelles
form around
of of
CoQ
) protected human
neuronal
10 (WS-CoQ
cells against oxidative stress-induced cell death in in vitro human teratocarcinoma and
human neuroblastoma cell culture models (Sandhu et al., 2003; McCarthy et al., 2004;
Somayajulu-Nitu et al., 2005). Furthermore, it has been shown that WS-CoQ10 not only
decreased oxidative stress, but stabilized mitochondria and prevented Bax-induced
mitochondrial permeabilization (Naderi et al., 2006). Most importantly, in a recent study
with a paraquat-induced Parkinson’s disease rat model, WS-CoQ10 was shown to be
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effective in preventing DA neuronal loss in the SN and amelioration of PD-related
behvioural symptoms in rats (Somayajulu et al., 2009).

1.9. Role of Glial Cells in Preventing Neuronal Cell Death
Glial cells are non-neuronal cells that provide support to neurons. There are four
different types of glial cells: oligodendrocytes, ependymal, microglia and astrocytes.
Oligodendrocytes supply the structural support of the myelin sheath that covers and
protects neuronal projections. Ependymal cells compartmentalize membranes and create
barriers. Physical aid is given by microglia that act as phagocytes for damaged neurons.
Astrocytes provide biochemical support to neurons by transporting nutrients from the
blood to neurons, maintaining homeostasis by absorbing excess potassium and
neurotransmitters, and by secreting neurotrophic factors needed for growth and sustaining
neurons (Purves et al., 2008).

1.9.1. Neurotrophic Factors
The word ‘trophic’ comes from the Greek trophe for “nourishment.” There are
four main families of neurotrophic factors: neurotrophins, glial derived neurotrophic
factors,

neurotrophic

cytokines,

and

cerebral

dopamine

neurotrophic

factors/mesencephalic astrocyte-derived neurotrophic factors.
In the central nervous system (CNS), neurotrophic factors (NTFs) are secreted by
astrocytes, where they control differentiation, growth, plasticity and survival of neurons
(Purves et al., 2008). Certain neurotrophins provide support to specific types of neurons.
Highly selective action is based on localization and expression of the receptor on the
target neuron. For example, brain derived neurotrophic factor (BDNF) is expressed only
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in the CNS and has high affinity to tyrosine-related kinase B (TrkB) receptors. These
receptors elicit either pro-survival or pro-apoptotic actions depending on the cascade that
follows receptor binding (Figure 14).	
  	
  

Figure 14: Neurotrophin receptors. BDNF binds to TrkB receptors that encourage cell
survival.
Glial derived neurotrophic factor (GDNF) belongs to the pro-survival family of
ligands (GLF) for dopaminergic neurons in vitro (Lin et al., 1993) and has shown to
trigger synaptogenesis in hippocampal neurons (Ledda et al., 2007). Removing GDNF
expression exhibited DA neuronal loss in both the SN and VTA as well as a loss of
striatal DA terminals (Pascual et al., 2008; Kramer et al., 2007). Other in vitro studies
have shown that the mechanism of GDNF protection may be promoting survival by
inhibiting death receptor and caspase-dependent pathways, without mitochondrial
involvement (Yu et al., 2008). GDNF has also been found to inhibit microglia activation,
decreasing the inflammatory response associated with neurodegeneration in vitro (Xing et

28

al., 2010). In vivo studies with MPTP treated mice show that GDNF protects DA neurons
in the SN, striatal dopamine and fibers (Schober et al., 2007).
In new research, clinical trials administering GDNF to PD patients have been
conducted, but were stopped due to uninspiring results and suboptimal delivery of GDNF
to the brain (Lang et al., 2006). Two new DA neuron NTF homologs have been recently
discovered: cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocytederived neurotrophic factor (MANF) (Lindholm et al., 2007; Petrova et al., 2003).
However, not much is known in terms of signaling cascades for neuroprotection
mechanisms as of yet. NTFs have also been studied in vivo, but they do not cross the
BBB and must be directly injected into brain tissue.

1.10. Objectives
1. Assess the toxicity and progressive loss of dopaminergic neurons following
paraquat injections.
2. Quantify the bioavailability of CoQ10 post-treatment.
3. Evaluate the efficacy of neuroprotection by post-injection feeding (therapeutic
treatment) of WS-CoQ10.
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CHAPTER II
METHODS
2.1. Animals and Animal Care
Long-Evans Hooded male rats (3 months old) were purchased from Charles River
Breeding Farms in St. Constant, Quebec. Upon arrival, animals were handled everyday
for one week prior to any behavioural or biochemical experimentation and their ears were
punched for identification. Rats were housed in group cages (3-4 rats per cage) with the
room temperature maintained at 20oC. Due to their nocturnal nature, rats were put on a
reversed 12-hour light: 12-hour dark cycle to ensure animals were awake during
behavioural testing during the day.
All animal care, treatments, and procedures were approved by the University of
Windsor Animal Care Committee (AUPP#10-15) in accordance with the Canadian
Council for Animal Care guidelines.

2.2. Behavioural Assessment
2.2.1. Pole Test
The pole test was used to assess the agility and locomotion of the treated rats. A
meter tall pole was covered in burlap and positioned in a bin filled with bedding.
Animals were put on the bedding for 2 minutes to become acclimatized and then put at
the top of the pole. If the rat did not move, it was taken off the pole after 3 minutes. A
video was recorded and the time it took for the rat to climb down the pole was calculated,
as well as if the animal fell off or not. This test was conducted once a day for three days
only after injections.
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2.2.2. Turn Around Test
The turn around test was used to determine the speed and agility of the animals
after treatment. Rats were placed upside down at the bottom of a metal lattice six-foot
climbing wall, with a platform on top and gap at the bottom. Animals were video taped
and timed to evaluate how long it took each rat to reach the top platform. They were
tested once before injections for baseline times, once during injection and once after
injections.

2.3. Experimental Design
2.3.1. Experiment I: Assessment of Paraquat Toxicity Over Time
To determine if paraquat induces dopaminergic neuronal loss over time
(progressively), the toxicity of paraquat was evaluated. This experiment included twelve
rats, each receiving a total of five intra-peritoneal injections, once every five days.
Control rats received injections of phosphate buffered saline (PBS, 10 mg/kg) [8 g NaCl,
0.2 g KCl, 2.68 g Na2HPO4•7H2O and 0.24 g KH2PO4 in 800 mL of dH2O, pH = 7.6] and
normal drinking water throughout. Experimental rats received 10 mg/kg injections of
paraquat (methyl viologen, Sigma-Aldrich, Cat. No. 856177) solution dissolved in PBS
(10 mg/mL) and normal drinking water throughout. The animals were then sacrificed 48
hours, 2 weeks and 1 month after the last injection (Table 3, Figure 15). One rat from
each group was sent to NRC in Ottawa for HPLC analysis of paraquat levels in the brain,
liver, and blood plasma. The remaining rats from each group were used for tyrosine
hydroxylase immunohistochemistry, and stereologer neuronal cell counting.
biochemical assays were conducted and no behavioural experiments were conducted.
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No

Table 3: Groups for Experiment I: Assessment of paraquat toxicity over time.
Rat groupings based on injections and duration of time after last injection for sacrifice.
Injection

Treatment

Number of rats

Sacrificed
(post-injections)

Saline

Water

3

48h/2wk/1mo

Paraquat

Water

3

48 hours

Paraquat

Water

3

2 weeks

Paraquat

Water

3

1 month

(1 every 5 days)

Figure 15: Timeline for Experiment I: Assessment of paraquat toxicity over time.
2.3.2. Experiment II: Bioavailability and Pharmacokinetics of WS-CoQ10
To assess the bioavailability of WS-CoQ10, levels of CoQ10 were measured by
high performance liquid chromatography (HPLC). Twenty-seven rats were divided into
two main groups, those that would receive a low concentration dose (50 µg/mL) and
those that would receive a high concentration dose (100 µg/mL) of WS-CoQ10 in their
drinking water. Sugar was also added to the drinking water to encourage consumption
(37.5 g/L). Animals were deprived of water for 23 hours and subsequently given one
hour of normal water (control rats) or water supplemented with WS-CoQ10 (experimental
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rats) in a low or high dose. Rats were caged individually for their hour of drinking and
levels consumed were measured. Animals were sacrificed 1, 3 and 6 hours after their
hour of drinking (Table 4, Figure 16). Rats were perfused with Tyrode’s buffer and brain,
blood, liver, kidney and heart samples were snap frozen and sent to NRC in Ottawa for
HPLC analysis. No behavioural experiments were conducted.

Table 4: Groups for Experiment II: Bioavailability and pharmacokinetics of WSCoQ10. Rat groupings based on treatment concentration and time sacrificed after WSCoQ10 consumption.
Treatment

Sacrificed (post-drinking)
1 hour

3 hours

6 hours

Water

1 rat

1 rat

1 rat

50 ug/mL WS-CoQ10

5 rats

5 rats

5 rats

100 ug/mL WS-CoQ10

3 rats

3 rats

3 rats

Figure 16: Timeline for Experiment II: Bioavailability and pharmacokinetics of WSCoQ10.

2.3.3. Experiment III: Assessment of Intravenous WS-CoQ10 Delivery
To see how quickly WS-CoQ10 is absorbed and metabolized, it was delivered
straight into the blood stream. Three rats were anesthetized and each received 5mg of
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WS-CoQ10 [50mg/mL stock, 1:1 PBS dilution, 200 µL injected] injected intravenously
through the tail vein. Animals were then sacrificed and perfused with Tyrode’s buffer
three hours after injections. Blood, brain, liver, kidney and heart samples were snap
frozen and sent to NRC in Ottawa for HPLC analysis. No behavioural experiments were
conducted.

2.3.4. Experiment IV: Assessment of WS-CoQ10 as a Therapeutic Treatment of PD
Since Parkinson’s disease is diagnosed in patients after more than 50% of their
dopaminergic neurons are lost, it is important to assess the protective effects of WSCoQ10 as a therapeutic treatment. Twelve naïve rats were divided into three groups: a)
control saline-injected rats given regular drinking water throughout, b) paraquat-injected
rats given regular drinking water throughout, and c) paraquat-injected rats given drinking
water supplemented with WS-CoQ10 (50 µg/mL, Table 5).

Animals were given one

injection every five days for a total of five injections. Twenty-four hours after the last
injection, animals were given their normal or supplemented water ad libitum, in group
cages for three weeks (Figure 17).
Behavioural assessments on the rotorod, horizontal ladder, turnaround, and object
recognition were conducted before, during, and after treatment. Sacrifices took place
three weeks after last injection. This experiment was repeated with the same number of
rats, groupings, injections, water supplementation and behavioural evaluations.
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Table 5: Groups for Experiment IV: Assessment of WS-CoQ10 as a Therapeutic
Treatment of PD. Rat groupings based on type of injection and type of treatment.
Injection

Treatment

Number of Rats

Saline

Water

6

Paraquat

Water

7

Paraquat

WS-CoQ10

12

Figure 17: Timeline for Experiment IV: Assessment of WS-CoQ10 as a Therapeutic
Treatment of PD.

2.4. Dissections
2.4.1. General Supplies
General supplies needed for dissections include: paper towels, straight/sharp
Deaver scissors, “mouse teeth” tissue forceps (for holding onto fur), thumb/serrated
dressing forceps (for holding the heart), half curved iris tissue forceps (for easy brain
collection), flat tipped forceps (for removing organs) and long serrated dressing forceps
(for holding back rib cage) were all purchased from the Chemical Control Centre or the
Biology stockroom, guillotine, pliers (for removing rat skull) purchased from Canadian
Tire, ethanol in squirt bottle, black dissection paint tray (Canadian Tire), cage paper
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(Biology building basement), timer, 50 mL Falcon tubes filled with ~30 mL
formaldehyde for immunohistochemical organ storage.

2.4.2. Tissue Collection for Immunohistochemistry and Biochemical Assays
To prepare the anesthetic chamber, the oxygen tank was turned on and the rat was
placed inside.

The dial on the isoflurane (Chemical Control Centre, Ref. 537401)

apparatus was turned to 5 and the rats were kept in the anesthetic chamber until they
appeared asleep (approximately 2-3 minutes). The animals were then transferred to the
dissection tray and an anesthetic mask was put over the nose. The skin under the forearm
was pinched to confirm the rat was asleep and could not feel pain.
Ethanol was used to moisten the fur on the abdomen and an incision was made
just under the xiphoid process of the sternum, vertically up to the neck on the ventral
aspect of the rat. A 255/8 gauge needle (BD Precision Glide Needle, Biology stockroom,
Ref. 00100370) with a 1mL syringe (BD, Biology stockroom) was inserted into the heart
and used to obtain ~1 mL of blood, which was then stored on ice in plasma separator
tubes (BD Biosciences Microtainer, Plasma Separator Tubes with Lithium Heparin, Ref.
365958). To perfuse the rat, a 12-gauge needle (Biology stockroom) was inserted it into
the left ventricle of the heart pointing up towards the left atrium. A small nick was made
to the right atrium. Tyrode’s buffer [8.76 g NaCl, 0.298 g KCl, 0.222 g CaCl2, 2.603 g
HEPES, 1 g dextrose, 1 g NaHCO3 and 0.06 g Na2HPO4 4H2O per litre of dH2O]
containing 114.28 mg of heparin (Sigma-Aldrich, Cat. No. H3393), to prevent blood
clotting, was gravity fed through hosing and the 12-gauge needle. The anesthetic mask
was taken off at this point.
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Once the fluid emerging from right atrium turned clear and there was
discoloration of the liver (identified by snipping the edge if not visible otherwise), the
Tyrode’s buffer was switched to 10% buffered formaldehyde diluted with PBS [8 g NaCl,
0.2 g KCl, 2.68 g Na2HPO4•7H2O and 0.24 g KH2PO4 in 800 mL of dH2O, pH = 7.4].
Perfusion was continued until limbs (including neck) became rigid.
The animal was then decapitated by guillotine and the heart, kidney, liver and
brain were collected. Samples that would be used for immunohistochemistry were fixed
by placing into 10% buffered formaldehyde filled falcon tubes for 24 hours at 4oC. Those
that would be used for biochemical assays were put into 5 mL Nalgene cryoware
cryogenic vials (VWR, Cat. No. 5000 0050), snap frozen in liquid nitrogen and then
stored at -80oC. Blood samples were spun at 4,000 r.p.m.; the serum was collected and
transferred to a 1.5 mL microcentrifuge tube (Axygen, Cat. No. 311-08-051), and stored
at -80oC.

2.4.3. Brain Harvesting
After decapitation, the scalp is first removed and the sides of the skull loosened at
the base with scissors. The skull was then removed with pliers by moving down the sides
and then across the top of the head. The curved forceps were used to pull the meninges
out of the way and the brain scooped out (using gravity and very gentle force). For
biochemical assays, the cerebellum was removed; the rest of the brain was sectioned
down the midline and separated into two hemispheres.
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2.5. Immunohistochemistry
2.5.1. Immunohistochemical Reagents
The following materials and reagents were used for immunohistochemistry:
microscope cover class 22 x 60 (UltiDent Scientific, Biology Stockroom, 170-C2260),
universal protein block, serum-free, ready to use (DAKO, Ref. X0909), antibody diluent
(DAKO, Ref. S0809), diamino benzamidine (DAB) (Sigma, Cat. No. D8001-5G),
Vectastain Elite ABC Kit containing goat serum blocking solution and avidin biotinylated
horse-radish peroxidase complex (ABC reagent) (Vector Laboratories, Cat. No. PK6101), DAB peroxidase substrate kit (Vector Laboratories, Cat. No. SK-4100), Cytoseal
(Thermo Scientific, Ref. 8310-16).
Antibodies: Affinity purified rabbit anti-tyrosine hydroxylase polyclonal antibody
(1:1000, Pel-Freez, Cat. No. P40101), rabbit anti-glial fibrillary acidic protein polyclonal
antibody (1:500, ABCAM, Cat. No. ab7260, Lot #6-R20948-a) and

goat anti-rabbit

biotinylated secondary antibody (Elite ABC kit, Vector Laboratories, Cat. No. PK-6101).

2.5.2. Dehydration and Paraffin Embedding
To prepare the rat brains for dehydration, after 24 hours the 10% buffered
formaldehyde was exchanged for 70% ethanol and incubated overnight at 4oC. The
brains were then dehydrated by an ethanol gradient: 30 minutes in 70% ethanol, 1 hour
each in 80% and 95% ethanol and 1 hour (x3) in 100% ethanol. The brains were then
incubated in xylene for 40 minutes (x2) and then paraffin wax overnight in a 60oC water
bath (Isotemp 202, Fisher Scientific).
The forebrain (at the optic chiasm) was removed, guided by a brain matrix (Ted
Pella Inc, Cat. No. 15054) and the rest of the brain was transferred to metal moulds (Lab
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Tek Plastic Co, patent number 2996762). It was then covered by paraffin wax (VWR,
Cat. No. 72050-030) supported by plastic embedding moulds (VWR, Cat. No. 25602766) and left to dry.

2.5.3. Tissue Sectioning
Midbrain tissue sections were cut on a microtome (Heidelberg HM 320), fitted
with disposable microtome blades (Triangle Biomedical Sciences, Cat. No. DMB-LP) at
40 µm initially (30 µm later on) spanning the entire substantia nigra region (-4.56 mm to
6.60 mm Bregma).

Sections were cut at 20 µm spanning the latter half of the

hippocampus region (-4.56 mm Bregma) and sections cut at 20 µm spanning the latter
half of the putamin (6.60 mm Bregma).

2.5.4. Slide Preparation
Two types of slides were used; Superfrost plus (Fisher, Cat. No. 12-550-18) and
normal microscope slides (Biology stockroom, reference number 00100418).

The

Superfrost slides were used as is for thinner sections (20 µm), tissue was placed into a
water bath at 43oC and scooped up with the slides. The regular microscope slides were
used for thicker 30 µm and 40 µm sections.
Since the thicker sections did not stay on the Superfrost slides, the normal
microscope slides were prepared multiple ways to determine the best method for adhesion
of the brain tissue. The preparation that was the most successful included using 30 µm
sections and coating the slides with egg white albumin (egg whites from the grocery
store). The albumin was applied to the slides by gloved finger and then left to dry for 2
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hours in a dust free chamber. Once the slides were dry, the 30µm sections were picked up
from a distilled water bath set at 40 oC and left in a dust free chamber to dry overnight
(~16 hours) at room temperature.

2.5.5. Bright-field Immunohistochemistry using 3,3’-diaminobenzidine (DAB)
Due to the purchase of new Stereologer software, the protocol for bright-field
immunohistochemistry using 3,3'-diaminobenzidine (DAB) was modified from previous
years.

Although optimum standardization of this protocol is still taking place, the

following method proved satisfactory.
All solutions were placed in glass Coplin jars (donated by NRC in Ottawa) and
slides were submerged in glass Coplin jar baskets (donated by NRC in Ottawa) unless
otherwise specified.
After dehydration, the tissue sections were deparaffinized by submerging them in
xylene (2x5 minutes); fresh xylene was exchanged after three uses. Sections were then
rehydrated using an ethanol gradient (5 minutes in 95% ethanol, 5 minutes in 70%
ethanol), then 5 minutes in dH2O. Next, slides were washed in tris-buffered saline (TBS)
[2 x 5 minutes; 12 g of Tris-HCl, 17 g of NaCl and 1 L of dH2O, pH = 7.2], incubated in
3% H2O2 for 40 minutes to block endogenous peroxidases and washed again in TBS (3 x
5 minutes). The slides were first blocked with avidin and biotin for 15 minutes each
according to the manufacturer’s protocol (Vectastain Elite ABC Kit, Vector
Laboratories). Next, they were blocked with the goat serum blocking solution for 30
minutes and then with universal serum-free protein block for another 30 minutes. The
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slides were incubated with primary antibody with 1% Triton in antibody diluent overnight
at 4oC in a humid chamber.
The next day slides were washed 3 x 5 minutes in TBS and then incubated in
secondary antibody for 1.5 hours. After another wash in TBS (2 x 7 minutes), ABC
reagent was applied for 45 minutes. The slides were washed again with TBS (3 x 5
minutes) and DAB was applied drop-wise to each tissue section. A colour change to dark
brown was visually monitored until the SN region could be identified (this was
supplemented by looking on the microscope). The reaction was stopped by submerging
the slides in dH2O (3 x 5 minutes) and then washed again in TBS (3 x 7 minutes). The
sections were dehydrated using 95% ethanol (2 x 5 minutes) and xylene (2 x 5 minutes).
The slides were then cover slipped using Cytoseal.

2.5.6. Stereologer Software
To obtain statistically significant data, Stereologer software was purchased from
Disector (Stereology Resource Center, Inc., Maryland, US) and used to count the TH
positive (DA neurons) in the substantia nigra. Out of approximately 40 midbrain sections
(-4.56 mm 6.60 mm Bregma), a total of ten sections were selected (every fourth) as a
representation of the SN region. These sections were then counted systematically using
the software prompts. See Appendix E for screen shots and step-by-step instructions.

2.6. Biochemical Assays
2.6.1. Biochemical Reagents
The following reagents were used for brain tissue homogenization and sample
preparation: homogenization buffer [50 mM Tris-HCl, 0.15 mM NaCl, 10 mM EDTA,
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1% TritonX-100, 1 mM PMSF, 1µg/mL pepstatin A and 1 µg/mL leupeptin, pH = 7.5],
Phosphate-buffered saline (PBS) [8 g NaCl, 0.2 g KCl, 2.68 g Na2HPO4 7H2O and 0.24
g KH2PO4 in 800 mL of dH2O, pH = 7.4], 4X loading dye [50 mM Tris-HCl, pH = 6.8,
100 mM dithiothreitol, 2% SDS, 0.1% bromophenol blue and 10% glycerol], bovine
serum albumin (BSA) (Sigma-Aldrich, Cat. No. A7906), Bio-Rad protein dye assay
reagent (Bio-Rad Laboratories, Cat. No. 500-0006).
The following reagents were used for Western blot assays: 12% SDS-PAGE
resolving gel [2.15 mL of dH2O, 1.5 mL of 40% acrylamide, 1.25 mL of 1.5M Tris (pH =
8.9), 50 µL of 10% SDS, 50 µL of 10% APS and 8 µL of TEMED], 12% SDS-PAGE
stacking gel [1.75 mL of dH2O, 300 µL of 40% acrylamide, 400 µL of 0.5M Tris (pH =
6.7), 25 µL of 10% SDS, 25 µL of 10% APS and 5 µL of TEMED], running buffer [14.4
g of glycine 1 g of SDS, 3 g of Tris HCl, 1 L of dH2O].
Antibodies: Affinity purified rabbit anti-tyrosine hydroxylase polyclonal antibody
(1:1000, Pel-Freez, Cat. No. P40101), rabbit anti-glial fibrillary acidic protein polyclonal
antibody (1:500, ABCAM, Cat. No. ab7260, Lot #6-R20948-a), rabbit anti-brain derived
neurotrophic factor (1:1000, Scanta Cruz Biotechnology, Cat. No. sc-546 Lot #I2309 or
Cat. No. sc-20981 Lot #J1810), rabbit anti-interleukin-β1(H-153) polyclonal antibody
(1:1000, Santa Cruz Biotechnology, Cat. No. sc-7884), affinity purified rabbit anti-nerve
growth factor (M-20) polyclonal antibody (1:1000, Santa Cruz Biotechnology, Cat. No.
sc-549), affinity purified rabbit anti-glial derived neurotrophic factor (D-20) polyclonal
antibody (1:500, Santa Cruz Biotechnology, Cat. No. sc-328), series of rabbit antiLRRK2 antibodies (Michael J. Fox Foundation, Cat. No. c68-7, c81-8, c5-8, c69-6, c412, Epitomic, Inc.), rabbit anti-beta actin antibody (Santa Cruz Biotechnology, Cat. No. sc-
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81178 Lot #131809), rabbit anti-tubulin antibody (Santa Cruz Biotechnology, Cat. No.
sc-9104) and polyclonal goat anti-rabbit HRP conjugate (DAKO, Cat. No. P0448).

2.6.2. Tissue Homogenization
Animals that were snap frozen for biochemical analysis were thawed on ice,
weighed, and minced with scissors. They were then homogenized in 10 times the volume
(10 mL of buffer for 1 g of tissue) in ice-cold homogenization buffer (pH = 7.5) for 30
seconds three times with 20-second intervals. The homogenates were then centrifuged
(Jouan CR3i) at 3,000 r.p.m. for 10 minutes in a T40 swing bucket rotor at 4oC. The
supernatant (cytoplasmic fraction), was transferred to a 50 mL Falcon tube and protease
inhibitors were added (LeuPep 1 µL/mL, PepA 1 µL/mL and PSMF 10 µL). The samples
were then aliquot (500µL) into microcentrifuge tubes and stored at -80OC for future
biochemical assay use.

2.6.3. Sample Preparation
To prepare samples for SDS-PAGE/Western blots, brain tissue homogenates were
thawed on ice, sonicated for 10 seconds (level 4) and spun on a Biofuge 15 centrifuge
(Heraeus Instruments) at max r.p.m. for 5 minutes at 4oC (in the cold room). The protein
content was then estimated using the Bradford Assay (described below). Samples were
aliquot by adding 20 mg of tissue homogenate to PBS (pH = 7.4) and 4X loading dye for
a total volume of 20µL. They were heated at 95oC on a heat block for 7 minutes and
stored at -20oC.
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2.6.4. Bradford Assay
To estimate the protein concentration in the tissue homogenate samples, a
Bradford Assay was performed using the Bio-Rad Laboratories protocol. A standard
curve was established using 1 mg/mL BSA for known concentrations ranging from 0.002
mg/mL to 0.025 mg/mL.
For protein estimation 2 µL of sample tissue was added to 798 µL of dH2O and
200 µL of Bio-Rad protein assay reagent to a plastic 1 mL cuvette in triplicate. The
samples were mixed with a pipette and incubated at room temperature for 5 minutes. The
absorbance of the standards and samples were measured using a Genesys UV-Visible
Spectrophotometer at 595 nm. Microsoft Excel was used for data analysis.

2.6.5. SDS-PAGE Western Blot
Protein samples were prepared as stated above, thawed, vortexed, centrifuged and
loaded (20 µg of protein per well) onto a 12% SDS-PAGE. The gel was run in running
buffer until the dye front ran off the bottom of the glass plate.

The protein was

transferred in transfer buffer [10X: 1.45 g of Tris (hydroxymethyl) base, 7.2 g of Glycine,
200 mL of methanol and 800 mL of dH2O, pH=7.6] onto a nitrocellulose membrane for
1.5 hours at 0.12 constant amps.
To insure equal loading of protein, the membrane was incubated in PonseauS [100
mg of Ponceau, 5 mL of acetic acid and 95 mL of dH2O] for 10 minutes on a rocking
platform (VWR, model 200). It was then washed with dH2O until bands were visible, and
imaged on an HP scanjet 4600 scanner. The membrane was blocked in 5% skim milk in
TBST [12 g of Tris-HCl, 17 g of NaCl, 1 mL of Tween, 1 L of dH2O, pH = 7.6] for 1
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hour at room temperature on the rocking platform and then incubated in primary antibody
with 2% skim milk overnight at 4oC on a nutating mixer (Gyromini, Labnet).
The next day the blots were washed with TBST (15 minutes, 3 x 5 minutes), then
incubated in secondary antibody in 2% skim milk solution for 1 hour at room temperature
on rocking platform. The blots were washed in TBST, as mentioned previously and
developed using ChemiGlow West kit as per the manufacturer’s protocol (Sigma Aldrich,
Cat. No. C9107). The blots were then imaged on an Alpha Innotcech Corporaation
Imaging System.

2.6.6. Glutathione Assay
To determine levels of oxidative stress a GSH assay was used. Tissue samples
were prepared as per section 5.1 describes and 2 µL of each were loaded onto a 96 well
translucent, flat-bottomed plate (Sarstedt, Cat. No. 83-1835-300). To each well 100 µL
of reaction mixture [1 mM NADPH and 100 units of GSH reductase in dH2O] was added.
The plate was then incubated for 20 minutes at 37oC.
A standard curve was made by using 1 mM GSH and 50 µL of this was added to
the 96-well plate along with 150 µL (to standards) and 100 µL (to samples) of
dithiobisnitrobenzoic acid (DTNB) in 0.1 M PO4 buffer (pH = 8.0) and incubated again
for 15 minutes at 37oC. Endpoint absorbance at 405 nm was measured using a Wallac
Victor3 1420 multilabel counter plate reader (PerkinElmer).

A Bradford assay was

performed to estimate the protein concentration in each tissue sample. The amount of
oxidative stress was expressed in GSH per microgram of protein (g/mol) and data was
represented using Graph Pad Prism.

45

2.6.7. Lipid Peroxidation
Lipid peroxidation was measured in order to determine levels of oxidative stress
occurring in the brain of treated animals. In 1.5 mL microcentrifuge tubes, 100 µL of
brain tissue homogenate was added to 1 mL of thiobarbituric acid (7 g trichloroacetic
acid, 0.185 g thiobarbituric acid, 12.5 mL of 0.25 M HCl in 37.5 mL of dH2O). The tubes
were incubated on a heat block at 100oC for 20 minutes with the lids open so caps did not
pop.

Once the tubes reached room temperature, their absorbance at 535 nm was

measured using a Genesys UV-Visible Spectrophotometer.
A standard curve was made using 100 µM malondialdehyde (MDA), as well as a
Bradford assay, to determine concentration. Levels of lipid peroxidation was represented
per microgram of protein, calculated on a Microsoft excel worksheet and displayed on
Graph Pad Prism.

2.7. Statistical Analysis
Unless otherwise stated, all the statistical data is represented as the mean ± SEM
of at least three independent animals. Statistical analysis was performed by two-way
ANOVA tests followed by post-hoc Dunnett’s multiple comparison tests, using Graph
Pad Prism.
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CHAPTER III
RESULTS
The cause of Parkinson’s disease is still unknown, and there are currently no
treatments for the disease beyond symptomatic relief. The aim of this study was to
establish an environmental toxin-induced animal model of Parkinson’s disease that shows
its progressive pathogenesis, as well as to quantify the bioavailability of a water-soluble
formulation of CoQ10, and to evaluate its neuroprotection as a therapeutic treatment
against Parkinson’s disease.

Troubleshooting
The majority of time on this project was put into standardizing the
immunohistochemical methodology for the Stereologer software. Please see Appendix A
for a summary of the tissue staining techniques used throughout these studies.

3.1 Paraquat Toxicity Suggests Progressive Dopaminergic Neuronal Cell Death
Parkinson’s disease is both progressive and chronic, with the progressive loss of
DA neurons in the SNpc as the most apparent contributing factor. Normal aging humans
lose many brain cells throughout the course of their lives, including DA neurons;
however, those with PD lose them at an alarming rate. Therefore, to create a realistic
model of Parkinson’s disease, the effect of paraquat toxicity on the brains of Long Evans
hooded rats, specifically the progressive loss of DA neurons in the substantia nigra, were
assessed.
As mentioned, tyrosine hydroxylase is the rate-limiting enzyme responsible for
converting tyrosine into dihydroxyphenylalanine (DOPA), which is the first step of
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dopamine synthesis in neurons (Figure 1). Tyrosine hydroxylase has also been shown to
decrease after dopaminergic insult (Emborg, 2004), and thus a good marker for DA
neurons. Tyrosine hydroxylase positive neurons in the substantia nigra region of the
midbrain, spanning approximately Bregma -4.56 mm to Bregma 6.60 mm (Paxinos &
Watson, 2005) of both paraquat-injected and saline-injected rats were counted using
stereological software. Stereological software was also used to compare the substantia
nigra volume and mean cell volume of DA neurons of animals receiving paraquat
injections with those that received saline injections (control animals).
Counting of the TH positive neurons in the substantia nigra revealed a 15%
decrease of DA neurons when comparing PQ-injected to the saline-injected control
animals that were sacrificed 48 hours after injections (Figure 18a). Furthermore, after 2
weeks and 1 month post-paraquat injection, the number of TH positive neurons decreased
approximately 40% (Figure 18a). Also observed was a 50% decrease in SN volume after
both the 2-week and 1-month time points compared to control (Figure 18b). The mean
volume cell of DA neurons did not differ from control throughout the three time points
(Figure 18c). Visual representations of TH positive neurons in the substantia nigra region
support this data (Figure 18d). Due to a low number of rats in each group (n = 2),
statistical analysis could not be conducted.
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a)

c)
c)

b)

d)
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Figure 18: Paraquat injections suggest progressive loss of dopaminergic neurons. a)
Dopaminergic neurons (TH positive cells) in the substantia nigra decrease in number over
time after paraquat injections, b) volume of the substantia nigra region of the midbrain
shows parallel results to TH positive numbers, c) mean cell volume of TH positive
neurons stay consistent throughout timeline, d) photomicropgraph representing TH
positive neurons in the substantia nigra region. Control animals were saline injected.
Values expressed as mean ± SEM, n = 2. Scale bar = 100 microns.

49

3.2. Bioavailability and Pharmacokinetics of WS-CoQ10
To prepare for clinical trials, it was necessary to determine if WS-CoQ10 could be
orally ingested, absorbed by the intestines, and delivered to the brain. Three tissues were
evaluated for the absorption and metabolism of WS-CoQ10 administered orally via the
rats’ drinking water: blood plasma, liver, and brain. This experiment was the first to
evaluate the bioavailability of the water-soluble formulation of coenzyme Q10.
Rats were divided into two main groups: those that would receive a low
concentration of WS-CoQ10 (50 µg/mL), and those that would receive a high
concentration of WS-CoQ10 (100 µg/mL) in their drinking water. The rats were further
subdivided into sacrifice time (see Section 2.3.2. for clarification).

The different

concentrations of WS-CoQ10 were used to determine which concentration was necessary
to deliver the effective dose of the compound. The data demonstrated that the higher
concentration was not necessary since the lower concentration delivered very similar
amounts of the compound to the brain tissue. Data is not shown. Since there was no
difference in the levels of CoQ10 between the 50 µg/mL and the 100 µg/mL doses, the
results for the lower concentration only are shown.
The water-soluble formulation of CoQ10 is a method for delivering CoQ10;
therefore, for clarification this experimental data detects levels of CoQ10. Results show
that CoQ10 is absorbed into the blood plasma very quickly and efficiently. The levels of
CoQ10 after one hour reach approximately 80 ng/mg of protein and then decrease
significantly to almost zero three hours after the supplemented drinking water was given
to the rats (Figure 19a). Results from the rat liver show that there is a substantial increase
(100%) in the levels of CoQ10 after one hour, and a 250% increase three hours after orally
ingesting the CoQ10 (Figure 19b). The most significant findings of this experiment were
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discovered with the bioavailability of CoQ10 levels in brain tissue (Figure 19c). As early
as one-hour post-oral administration of WS-CoQ10 results show significantly high levels
of CoQ10 in the brains of the test animals, jumping from 150 ng/mg of protein in control
rats to 383 ng/mg of protein. This is more than a 150% increase in CoQ10 levels in the
brain, which continues to increase up to 200% from control, even six hours after WSCoQ10 administration. It may be noted that the lower concentration of 50 µg/mL was
given as treatment to the rats in all other experiments conducted before, during, and after
these results.
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Figure 19: Bioavailability and pharmacokinetics of WS-CoQ10. a) Bioavailability of
water-soluble formulation delivery of CoQ10 in rat plasma, b) absorption and potential
metabolism of CoQ10 in rat liver, c) absorption of CoQ10 into brain tissue. Control rats
received normal drinking water only. Values expressed as mean ± SEM and analyzed by
ANOVA followed by Dunnett’s multiple comparison test, n = 3.
**p < 0.01, ***p < 0.001.
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3.3. Injecting WS-CoQ10 Intravenously
As a quick preliminary experiment, WS-CoQ10 was injected intravenously through
the tail of the rats to determine the bioavailability of the compound. This experiment was
performed to see if WS-CoQ10 could be administered directly into the blood stream and
compare to the results of the orally administered WS-CoQ10. It would be easier for
patients to take WS-CoQ10 orally, but if necessary, intravenous injection should be a
possibility as well. To see how quickly WS-CoQ10 could be absorbed and metabolized, it
was delivered straight into the blood stream.
Due to the low priority of this experiment and limited personnel of our
collaborators, the National Research Council of Canada (NRC, Ottawa), the HPLC
analysis of these rat samples was not completed. Therefore, no results were given for the
intravenous injection of WS-CoQ10.

3.4. Evaluation of WS-CoQ10 as a Therapeutic Neuroprotectant
Previous results in this laboratory have shown that WS-CoQ10 does in fact have
the ability to protect DA neurons both in vitro and in vitro models of Parkinson’s disease
when given prophylactically (McCarthy et al., 2004; Somayajulu et al., 2005;
Somayajulu-Nitu et al., 2009). While a prophylactic approach does have benefits towards
preventing PD, most people do not know they have Parkinson’s disease until more than
50% of their DA neurons are lost and the symptoms of PD begin to show. Therefore, it is
more beneficial and realistic to treat Parkinson’s disease after clinical diagnosis
(therapeutically).
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3.4.1. Dopaminergic neurons are protected by WS-CoQ10
To evaluate WS-CoQ10 as a therapeutic agent, animals were given WS-CoQ10 in
their drinking water immediately after receiving their fifth/last injection of paraquat (see
Section 2.3.4. for details of experimental design). Rat brain tissue samples were obtained,
sectioned, immunostained using anti-tyrosine hydroxylase as a marker of dopaminergic
neurons and counted in the substantia nigra, using stereological methods previously
mentioned. The results of these TH positive neuronal counts show that DA neurons in the
substantia nigra decrease significantly in number (60%), when subjected to paraquat toxic
insult compared to control rats (Figure 20a). However, when these rats were given WSCoQ10 supplemented water following paraquat injections, the number of DA neurons in
the SN decreased by only 40% compared to control rats (Figure 20a). Illustrated in Figure
20b, control animals (Sal + H2O) had dense, darkly stained TH positive neurons, whereas
paraquat-injected, untreated (PQ + H2O) animals had a large area lacking DA neurons.
The most striking result is paraquat-injected, treated (PQ + WS-CoQ10) rats, in which you
can see some loss of DA neurons, but considerably more than paraquat-injected, untreated
(PQ + H2O) animals (Figure 20b).
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Figure 20: Neuroprotection of dopaminergic neurons by WS-CoQ10.
Photomicrographs of a) control rats b) paraquat-injected untreated rats and c) paraquatinjected WS-CoQ10 treated rats, n = 7. Scale bar = 100 microns. Values expressed as
mean ± SEM, and analyzed by ANOVA followed by Dunnett’s multiple comparison test,
**p < 0.01.
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3.4.2. Biochemical markers of oxidative stress
Biochemical results were obtained from brain tissue homogenates to shed light on
the potential mechanism of WS-CoQ10 neuroprotection. A glutathione (GSH) essay was
conducted in order to evaluate levels of oxidative stress with and without WS-CoQ10
treatment.

Figure 21a shows a significant decrease (40%) of reduced glutathione

following paraquat injections compared to control, implying an increase in reactive
oxygen species. Rats treated with WS-CoQ10 supplemented water showed only a 20%
decrease in reduced glutathione.
A lipid peroxidation assay was also performed to assess the level of oxidative stress
between control, paraquat-injected and WS-CoQ10 treated rats. Figure 21b shows lipid
peroxidation increase by approximately 50% in paraquat-injected rats, and approximately
25% in WS-CoQ10 treated rats.
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a)

b)

Figure 21: Markers of oxidative stress. a) Levels of reduced glutathione, n = 8, and b)
levels of lipid peroxidation compared to percentages of control, n = 3. Values expressed
as mean ± SEM, and analyzed by ANOVA followed by Dunnett’s multiple comparison
test, *** p < 0.001.
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3.4.3. Behavioural Results
Behavioural data was collected before, during and after paraquat injections (see
Section 2.3.4. Figure 17 for experimental timeline). These tests were conducted by Dr.
Cohen’s laboratory and Dr. Cohen consolidated results. Figure 22 illustrates that on the
first day of testing rats injected with paraquat and untreated spent approximately 100
seconds climbing down the role, compared to paraquat-injected, treated (WS-CoQ10) rats
that spent only 45 seconds doing so, less than half the amount of time. Rats were
subjected to this pole test only after paraquat injections.
A second behavioural test was the vertical climb-up test; also known as the turn
around test (Chapter II, 3.4). The rats were subjected to this test before, during and after
paraquat injections. Figure 23 illustrates that post-paraquat injections, animals that were
untreated spend approximately 16 seconds reaching the platform; whereas WS-CoQ10
treated rats took 9 seconds (approximately 1.8 times quicker than untreated).
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Figure 22: Pole Test. Time for control (blue), untreated (red) and treated (green) rats to
climb down a pole. Tests conducted post-paraquat injections. n = 27.

Figure 23: Vertical Climb-up Test. Time taken for control (blue), untreated (red), and
treated (green) rats to climb up to a platform. n = 27.
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CHAPTER IV
DISCUSSION
4.1. Overview
The current study was designed to induce Parkinsonian symptoms in a rat animal
model using the herbicide, paraquat. Intervention with a water-soluble formulation of
coenzyme Q10 was introduced as therapeutic treatment for slowing or halting the
progression of the disease by protecting dopaminergic neurons. The results of this study
confirmed paraquat as an environmental toxin able to induce progressive dopaminergic
cell death in a rat model of Parkinson’s disease, and treatment with WS-CoQ10 was able
to provide neuroprotection. There were also high levels of CoQ10 found in the brain,
liver, and blood plasma of rats that were given water-soluble CoQ10 in their drinking
water, demonstrating the ability of the compound to cross the blood brain barrier.

4.2. Animal Models of Parkinson’s Disease
The pathogenesis of Parkinson’s disease is not clearly understood; there are many
underlying factors from environmental to genetic and everything in between. Therefore,
when studying a neurodegenerative disease, such as Parkinson’s, suitable laboratory
models are needed. While cell culture-based assays are an informative approach to study
the basics of the disease and potential treatment at the cellular level, in vitro observations
are often not akin to what happens in complex organisms, such as the human brain. On
the other hand, human subjects are not readily available for brain research; therefore,
feasible animal models must be designed to relate as closely as possible to the humanbased disease. As always, when conceiving an animal model for neurodegenerative
studies, there are both benefits and drawbacks, such as reproducibility, incomplete
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pathogenesis and the ability to incorporate transgenes, to name a few. Until there is a
“perfect” animal model for studying Parkinson’s disease, the appropriateness of the
model selected is based upon objectives and conceivable outcomes of the experiment.
In 1915, Long and Evans were the first to cross female, white Wistar rats with
male, wild gray rats creating what are now called Long Evans Hooded rats. These rats
are general multipurpose models, mainly used for behavioural studies (Charles River
Laboratories, Inc., criver.com), including behavioural deficits in animal models of
Parkinson’s disease (Rane & King, 2011; Courtiere et al., 2011; Klein et al., 2011). The
Long Evans Hooded rat has long established protocols for behavioural studies in Dr.
Cohen’s laboratory at the University of Windsor Psychology department. These rats are
easy to handle and train, cooperative, and have more brain complexity than the mouse.
The current neurodegenerative model developed previously by this laboratory of
five intra-peritoneal injections of paraquat has shown to induce dopaminergic cell loss in
the SN of Long Evans Hooded rats, without damaging major organs due to toxicity
(Somayajulu-Nitu et al., 2009). This has been recognized as an acceptable way of
inducing Parkinsonian symptoms: substantia nigra dopaminergic cell loss, mitochondrial
dysfunction, increased oxidative stress and behavioural deficits. The only downside is
that this model lacks the inclusion of Lewy bodies found in humans who have PD. Since
the aim of this study was to develop a neuroprotectant, a “fidelity model,” defined as a
model that reproduces the maximum number of characteristics of the original disease,
was desired (Bove & Perier, 2011).
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4.3. Paraquat as an environmental toxin-induced model for Parkinson’s Disease
A number of toxins could have been used to induce Parkinsonism in a rat model;
however, paraquat was chosen for the following reasons: i) although MPTP is an
excellent, consistent model, rats are relatively resistant to it (Przedborski et al., 2001),
dopaminergic cell death is not progressive, and it is a synthetic toxin that no human
would come in contact with besides those using synthetic heroin, ii) rotenone is not very
toxic to humans, and unstable in the environment (Bove et al., 2005); it shows nonspecific toxicity in rats, and behavioural deficits are sometimes undetectable (Klein et al.,
2011), iii) 6-OHDA does not cross the BBB and can only be administered by stereotaxic
methods (Terzioglu & Galter, 2008; Mercanti et al., 2012).
Paraquat, the toxin of choice, is a broadleaf herbicide used widely throughout the
world (Dinis-Oliveira et al., 2008), although it was banned in Europe in 2007. The most
common exposure to paraquat occurs by ingestion, direct contact with skin, or inhalation
in enclosed areas such as greenhouses. After exposure, it can travel to all tissues, but is
mostly localized in the kidneys, as well as the lungs where respiratory failure becomes the
major cause of death (Suntres, 2002). Studies found that paraquat as an oxidative stress
producer is linked to PD, and exposure to paraquat not only amplifies the risk of
developing PD, but also increases the chances of early onset (Tanner et al., 2011; Liou et
al., 1997; Dhillon et al., 2008; Costello et al., 2009). For these reasons, including the
likelihood of contact, and correlation to human Parkinson’s disease, paraquat was chosen
as the environmental toxin to induce PD in Long Evans Hooded rats.
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4.4. Assessment of paraquat toxicity
Parkinson’s disease is characterized by the progressive loss of DA neurons in the
substantia nigra pars compacta. Normal aging humans lose many brain cells throughout
the course of their lives, including DA neurons; however, those with PD lose them in this
region of the midbrain at an alarming rate. The current study demonstrated that the five
intra-peritoneal injection regime previously studied (Somayajulu, 2009), suggests a
progressive loss of dopaminergic neurons. Comparable to when Parkinsonian symptoms
occur in human diagnosed PD (Jankovic, 2008), this rat model showed a 40% loss two
weeks, as well as one month following paraquat injections compared to the control. It is
important to note that the lifespan of a Long Evans Hooded rat is approximately two
years. Assuming the life expectancy of a human is 80 years of age, it is possible to
calculate that 48 hours is equivalent to 3 months of human life, 2 weeks is equivalent to
1.5 years of human life and 1 month is equivalent to 3.3 years of human life. Therefore,
this paraquat-induced animal model of Parkinson’s disease can develop PD much slower
(equivalent to 1.5 years in a human), than other established animal models and hence,
more true to the real life scenario. For instance, the MPTP model uses acute injections
and is non-progressive showing dopaminergic neuronal loss only days after
administration (Hattori & Sato, 2007).
With no cure for Parkinson’s disease within the sights of this generation, postdiagnosis treatment is the optimistic target for slowing or halting the progression of PD.
Current experiments for assessing the therapeutic neuroprotection of WS-CoQ10 provide
treatment immediately following paraquat injections. To further develop WS-CoQ10 for
clinical trials, subsequent experiments may use the time points obtained from this study to
determine when appropriate intervention with WS-CoQ10 for therapeutic treatment could
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take place. Sometime between two weeks and one month after the last injection of
paraquat in an animal model may be the appropriate time (when approximately 50% of
DA neurons are lost) to intervene with WS-CoQ10 treatment.

Using time point

estimations mentioned above, the window for intervention with WS-CoQ10 treatment for
Parkinson’s disease patients would be anywhere from 1 – 3 years after the time of
diagnosis.

Repetition with additional time points would allow for a more precise

prediction.
This experiment is preliminary due to the fact that only two animals were used in
each group and should be repeated in order to conduct statistical analysis. It is important
to keep in mind the variability that may accompany any animal model.

Rats, like

humans, may respond to insult differently; some may cope better with the toxin than
others, especially over time. A larger sample of rats would be needed to account for the
variability as is any case using an animal model.

4.5. Measuring the bioavailability and pharmacokinetics of CoQ10 with a watersoluble delivery system
Promising human pilot trials for treatment of Parkinson’s disease with CoQ10
showed that the compound was safe and tolerable in high doses up to 3000 mg/day, and
slowed the progression of symptoms by 44% within eight months of treatment (Shults et
al., 2004); however, the exact oil-soluble formulation of CoQ10 used was never
mentioned. The most recent phase III clinical trial for treatment of Parkinson’s disease
with CoQ10 was terminated because no significant differences were seen between those
taking CoQ10 and those taking a placebo (National Institute of Neurological Disorders and
Stroke, 2011). Therefore, to develop water-soluble CoQ10 for clinical trials it must be far
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superior to current formulations. It is well known that oral absorption of CoQ10 is
negligible due to its low solubility in water (4 ng/mL)(Westesen, 2000), leading to poor
absorption through the gastrointestinal tract and minimal amounts crossing the blood
brain barrier. One rat study found that only 2-3% of orally administered CoQ10 was
absorbed (Zhang et al., 1995). On the other hand, the water-soluble formulation has high
bioavailability and can certainly cross the BBB; results from the bioavailability study
show that there are much higher levels of CoQ10 found in the blood plasma (8000%
increase), liver (100% increase) and most importantly the brain (165% increase) after one
hour of drinking WS-CoQ10 treated water compared to controls.
Much research has been devoted to improving the delivery of CoQ10. Oil
suspensions, powered formulations, self-emulsified drug delivery systems, and
nanoparticle technology are all examples. Some of these formulations have increased
bioavailability (Kalenikova et al., 2008), and have shown to significantly increase CoQ10
levels in brain tissue in mice (Matthews et al., 1998; Smith et al., 2006).
CoQ10 absorption is similar to that of α-tocopheryl (vitamin E) because of its
lipophilic characteristics. Once orally administered CoQ10 reaches the gastrointestinal
tract, it emulsifies CoQ10 and creates a micelle, allowing it to be absorbed.

After

absorption, chylomicrons transport CoQ10 into the blood stream via the lymphatic system
(Katayama & Fujita et al., 1972). The water-soluble formulation developed by NRC uses
polyoxyethanyl α-tocopheryl sebacate acid (PTS, polyethelene glycol and vitamin E)
non-covalently linked to CoQ10 that form nanomicelles in aqueous solutions (Section
1.8.3.).

This formulation is enhanced three-fold: i) consumption is made easier by

solubilization in aqueous media, ii) vitamin E is present in the formulation, and iii) it is
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already in nanomicelle form. This may facilitate CoQ10 absorption by the intestines and
increase plasma CoQ10, and increase the capacity to reach brain tissue, since higher
plasma CoQ10 concentrations are necessary to facilitate uptake by peripheral tissues
(Kwong et al., 2002).
Recent studies with CoQ10 found that the optimal dose needed to see
neuroprotective effects was 200 mg - 1600 mg/kg/day in mice (Cleren et al., 2008). This
correlates to 14 g - 114 g/day for a 70 kg person. However, during the phase III clinical
trials of CoQ10, a maximum amount of 3.0 g/day was given to participants (National
Institute of Neurological Disorders and Stroke, 2011). The FDA has approved 14 g/day
for human consumption, but this dose was never tested. Furthermore, 14 g/day is quite a
sizeable amount for daily consumption. The 50 mg/mL concentration of WS-CoQ10
supplemented drinking water that was given to rats in this current study translates to
approximately 6 mg/kg/day (calculated from average animal weights and average amount
of WS-CoQ10 consumed, data not shown), and was readily available in brain tissue. This
translates to 0.42 g/day for a 70 kg person, a much lower and realistic effective dose than
those used in current clinical trials.
Further pharmacokinetic experiments should be conducted to determine the time
point at which the supplemental CoQ10 has fully left the system of the individual. The
time points presently selected revealed levels of CoQ10 still increasing in brain tissue after
6 hours. CoQ10 orally administered to humans showed two peaks in the serum occurring
at six hours and 24 hours in pharmacokinetic studies (Spindler et al., 2009). The second
peak may be potentially due to liver secretion of CoQ10 after uptake. Extending time
points from to 20 hours or even days may determine when subsequent doses are needed,
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evaluate the lasting effects of CoQ10, and measure plasma levels to see if there is a
threshold to CoQ10 absorption.

4.6. Evaluation of the efficacy of WS-CoQ10 as a therapeutic neuroprotective agent
It is understood that CoQ10 treatment of PD cannot cure nor reverse the adverse
affects of PD, but rather halt the progression and protect the remaining DA neurons after
clinical diagnosis. Previous studies have shown neuroprotection by WS-CoQ10 when
given prophylactically (Somyayjulu-Nitu et al., 2009); therefore, the next step is to
administer WS-CoQ10, as a therapeutic agent to more closely resemble the real-life
scenario.
Two important studies have shown the neuroprotective of effects of CoQ10 in an
MPTP mouse model by reducing damage to dopaminergic neurons, maintaining levels of
striatal dopamine, and increasing mitochondrial CoQ10 (Beal et al., 1998; Cleren et al.,
2008). However, these models and many others treated toxic insult in a preventative
manner (prophylactically), rather than treating after the toxic insult (therapeutically);
hence, this may be the first therapeutic report of CoQ10 neuroprotection. Results from
paraquat-injected, therapeutic WS-CoQ10 treated rats indicate a loss of DA neurons due to
paraquat toxicity (60% decrease), but was not as extensive in those who received CoQ10
supplemented water (30% decrease). Supporting biochemical assays showed decreased
levels of GSH (45%) in paraquat-injected animal groups and increased GSH levels in
treated rats (20% decrease). Since glutathione combats reactive oxygen species, this must
mean WS-CoQ10 treatment can offer additional antioxidant duties, thus reducing the need
of GSH, and accounting for the reduction of glutathione levels. Behavioural studies show
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that paraquat induced a reduction in motor ability, which was alleviated by therapeutic
treatment with WS-CoQ10.

4.7. Potential mechanisms of WS-CoQ10 Neuroprotection
Recent studies have found that patients with Parkinson’s disease have lower levels
of CoQ10 in their blood (Mischley et al., 2012). It may be that a threefold mechanism is
responsible for the neuroprotective effects of WS-CoQ10 in an animal model of PD. First,
CoQ10 acts as a mitochondria stabilizer that effectively shuttles electrons between
complexes of the ETC, and in doing so increases the efficiency of ATP output. By not
allowing electrons to leak out and produce reactive oxygen species with nearby
molecules, such as molecular oxygen, mitochondrial membrane potential is maintained.
When membrane potential is kept intact no pro-apoptotic elements are released; therefore
providing no incentive for apoptosis to occur.
Some speculate that neuroprotection with WS-CoQ10 may increase viability in
cells that should routinely die by apoptosis, and consequently could initiate cancer. It is
known that oxidative stress is a major contributing factor in developing Parkinson’s
disease; if DA neurons are programmed to die via apoptosis, they will do so independent
of oxidative stress.
The second is that CoQ10 can act as an antioxidant. As mentioned previously,
CoQ10 transports electrons along the electron transport chain; therefore it is a reducing
agent that can quench reactive oxidative species by accepting radical electrons. Since
there is increased oxidative stress in PD patients, it is logical that CoQ10 could be used to
combat it. Vitamin E is also a large component of the water-soluble formulation that can
also act as antioxidant for oxidative stress. In fact, in humans, vitamin E has been shown
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to lower the risk of developing Parkinson’s disease, delaying the need for L-dopa
treatment in PD patients, and exhibiting some neuroprotective effects (Khanna et al.,
2005; Bostanci et al., 2010; Chao et al., 2012). Also, animals deficient in Vitamin E were
more susceptible to the toxic effects of paraquat, but additional supplementation to nondeficient animals did not provide significant protection (Suntres, 2002). It has been
suggested that the insolubility of vitamin E might contribute to its ineffectiveness.
The third mechanism of neuroprotection may be by activating glial cells,
especially astrocytes. Astrocytes are known to produce neurotrophic factors and increase
levels of GSH in order to combat ROS production due to toxic insult. Cell culture studies
using fetal rat cortical neurons discovered that cell viability increased when subjected to
paraquat, by co-culturing astrocytes with the cortical neurons. These astrocytes increased
the levels of GSH that in turn reduced ROS production (Rathinam, 2012). Their findings
coincide with the GSH levels found in rats that were either given WS-CoQ10 treatment or
non-supplemented drinking water after paraquat-injection.
Neurotrophic factors such as BDNF, GDNF, NGF and CDNF have all been shown
to contribute to neuronal support and growth. However, they were found in extremely
variable amounts in rat brain tissue homogenates of those treated and untreated with WSCoQ10 in this study (data not shown). Specifically concerning GDNF, levels of this
neurotrophic factor obtained by stereotactic methods in human brains were equal between
control and PD patients (Mogi et al., 2001). This could mean that the disease does not
affect the amount of GDNF present. Then again, GDNF is still a good candidate as a
therapeutic agent for PD because of its positive neurotrophic effect on DA neurons. In
contrast, levels of BDNF and NGF in human brains were much lower in PD patients than
control, specifically in the nigrostriatal regions (Mogi et al., 1999). If it were possible to
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increase levels of these neurotrophic factors with WS-CoQ10 it would surely help protect
DA neurons. Supporting studies such as transfecting astrocytes with the transcription
factor Pitx3, which is expressed mainly in DA neurons in the SN, causes them to upregulate BDNF and GDNF and protect DA neurons from toxic injury (Smidt et al., 1997;
Yang et al., 2008).

4.8. Future Studies
The majority of the time and effort put into this project was in an effort to
standardize a new protocol for bright field microscopy on the Stereologer software. Now
that it has been standardized to satisfaction, these experiments should be repeated with a
larger number of rats to obtain statistically significant data. This study clearly shows that
WS-CoQ10 can provide neuroprotection to dopaminergic neurons in the substantia nigra,
and that it has high bioavailability. Next, it is important to see what happens when some
of the parameters of these experiments are changed, such as those discussed below.
These types of studies will be required to progress WS-CoQ10 towards clinical trials.
Since Parkinson’s disease is an age related neurodegenerative disorder, repeating
therapeutic WS-CoQ10 treatment on aged rats would better reflect the real life scenario of
the disease. The rats used in these current studies are approximately five months old at
sacrifice. Aged rats would have to be at least 12 months old to signify old age, which is
comparable to onset of PD in humans, since early onset is defined as developing PD
before 40 years of age (Poorkaj et al., 2005). Investigation of whether age affects the
severity of paraquat toxicity on dopaminergic neurons with prophylactic treatment using
WS-CoQ10 was conducted revealing that aged rats showed a greater loss of TH positive
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(Somayajulu-Nitu, 2009). Therefore, it would be essential to examine the efficacy of
neuroprotection from WS-CoQ10 in a therapeutic manner with aged rats.
The purpose of the paraquat toxicity study was to determine when an appropriate
time for intervention with WS-CoQ10 would be most realistic and effective.

After

repeating that particular experiment to gain better statistical data, a subsequent study
should be conducted by delaying WS-CoQ10 intervention until the appropriate time
indicated from the first experiment. This study would also more realistically reflect the
scenario and time of PD diagnosis for human patients.
From the perspective of the stakeholders funding this project (Michael J. Fox
Foundation), a dose-dependent study of WS-CoQ10 is necessary for preclinical
development. Previous studies have examined paraquat toxicity in various rat tissues
(Somayajulu-Nitu, 2009), but evaluation of potential toxicity of WS-CoQ10 did not
accompany this data. Therefore, a study should include WS-CoQ10 doses higher (2x, 5x,
10x, etc.) than are currently being used (6 mg/kg), and tissue sent to pathologists for
analysis to see if there is toxicity due to high concentrations of CoQ10. Alternatively,
studies on lower doses of WS-CoQ10 should also be conducted. It would benefit business
partners (more cost-effective) and patients (a smaller amount to ingest) alike, if less of the
compound is needed to show neuroprotection of DA neurons.
Another important component of the overall project is to develop a therapeutic
treatment regime for WS-CoQ10 to be used as a nutroceutical to slow or halt the
progression of PD. An intervention-withdrawal experiment would assess WS-CoQ10
neuroprotection, when treatment is removed for a period of time. The intervals and
duration of withdrawal should be variables independently examined, to determine if
neuroprotection is temporary or continuous.
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Results from these experiments should

establish if it is essential for patients to consume WS-CoQ10 throughout their lives, or on
a set schedule.
The mechanism of neuroprotection of WS-CoQ10 still needs to be elucidated,
including the role of mitochondria and oxidative stress, as well as neuroinflammation. So
far, it has been identified that astrocytes are activated by WS-CoQ10 treatment. This can
be looked into further by probing brain tissue samples (western blot analysis and
immunohistochemical methods) with glial fibrillary acid protein (GFAP), which identifies
activated astrocytes.

Identifying which neurotrophins and cytokines are elevated or

diminished during paraquat-inducted toxicity and WS-CoQ10 neuroprotection may cause
inspiration for further initiatives with experimental design. While results from western
blot analysis for levels of neurotrophins in brain tissue homogenates have been too
variable to be deemed credible, other techniques such as ELISA and microarrays should
be sensitive enough to eliminate any variability.
It should be addressed whether WS-CoQ10 acts directly to reduce paraquat or
indirectly by reducing paraquat-induced reactive oxygen species. Measuring levels of
ROS by in vitro ROS assays using tissues homogenates would allow for a comparison
between paraquat-injected and WS-CoQ10 treated rat samples. If WS-CoQ10 is acting
directly on PQ, the levels of ROS should increase in WS-CoQ10 treated samples
compared to the control. Assessment of the three compounds: WS-CoQ10, O2, and PQ, to
see if there is a higher propensity for reducing one over the other could be done by
measuring reduction potential (Eh). This is a measure, in volts, of the tendency of a
chemical species to acquire electrons by using reference electrodes. WS-CoQ10 may also
act by stabilizing mitochondria; thus, components that are released during cell death
(cytochrome c, AIF, etc.) could be measured as well.
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4.9. Conclusion
This report has indicated that the environmental toxin, paraquat, induces loss of
dopaminergic neurons in the substantia nigra region of the midbrain of Long Evans
Hooded rats, indicating an animal model representative of Parkinson’s disease. For the
first time it is clearly shown that the current water-soluble formulation of coenzyme Q10 +
vitamin E increases the bioavailability of CoQ10 found in brain tissue. Ws-CoQ10 has also
shown antioxidative activity in the substantia nigra following toxic insult by paraquat.
These experiments are the first stages required to develop the water-soluble formulation
of CoQ10 for application in therapeutic clinical trials.
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APPENDIX A
TYROSINE HYDROXYLASE IMMUNOHISTOCHEMISTRY PROTOCOL TROUBLESHOOTING
Old Protocol

New Protocol

Current Standardized
Protocol

Slides

Super-frost Plus

Albumin coated

Super-frost Plus Heated

Tissue

Paraffin embedded

Paraffin embedded

Embedding matrix

Preparation

Moistened with water

Moistened w/ 0.1% Triton

Frozen at -20oC

Tissue Slicing

Microtome

Microtome

Cryostat

Section width

8 microns

40 microns

30 microns

o

Tissue Sections

Room temperature

45 C incubation

Room temperature

Blocking

DAKO Universal

3% H2O2 (40 minutes)

1% H2O2 (10 min)

(15 min)

Avidin (15 min)

Goat serum (30 min)

Biotin (15 min)

Universal block (30 min)

Goat serum (30 min)
Universal block (30 min)
Antigen Retrieval

N/A

10 mM sodium citrate

N/A

(15 min, water bath)
Primary Antibody

Rabbit anti-tyrosine

Rabbit anti-tyrosine

Rabbit anti-tyrosine

hydroxylase polyclonal

hydroxylase polyclonal

hydroxylase polyclonal

o

o

(overnight, 4 C)

(overnight, 4 C)

(overnight, 4oC)

Secondary

Sheep anti-rabbit IgG

Goat anti-rabbit

Goat anti-rabbit

Antibody

FITC (1 hour)

biotinylated (1.5 hours)

biotinylated (1.5 hours)

Chromogenic

N/A

ABC reagent (45 min, RT)

ABC reagent (45 min, RT)

DAB (Sigma)

DAB (Vector Lab kit)

Cytoseal

Paramount

Reagent
Coverslip

Mounting media

Mounting

containing DAPI

Microscopy

Fluorescence

Bright-field

Bright-field

Cell Counting

Manual

Unbiased Stereologer

Unbiased Stereologer

software

software
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APPENDIX B
ADDITONAL BEHAVIOURAL TESTS
Rotarod
The rotarod test was used to evaluate the balance of WS-CoQ10 treated animals as
per previously described (Somayajulu-Nitu et al., 2009), with the exception of a wider
rod (10 cm diameter). The rats were put on this rod for 2 minutes at a rate of 12 rotations
per minute in a forward direction with a clockwise rotation. Animals were tested once a
day for five days before injections to allow for training. They were also tested once
during injections and then for five days again after injections. A video of the rat on the
rotarod was taken and broken down into 500 frames where the amount of time the rat
spent facing forward, backward and turning was assessed. The position of the nose was
also recorded to evaluate how long the rat held its head up or down. Software tracking
program was used to aid in this process (7 Software, Inc, Montana, USA).

Activity Chambers
Activity chambers were used to evaluate the general movement of the animals. A
3 x 1 Plexiglas chamber contained vanilla scented bedding. Motion detectors or “photo
beams” were set up at four different locations within the chamber. The animals were put
in these activity cages only once for one hour after injections. The activity of the rat was
divided into three different parameters and recorded: i) the time it took for the rat to cross
from one side to the other, ii) how long it took to partially cross the chamber and iii) how
long it spent rearing.
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Incline Horizontal Ladder
A horizontal ladder with a slight incline was used to evaluate the animals’ fear of
falling and their stability. An apple was placed at the end for motivation to cross the
ladder. Metal rungs were placed along the ladder initially without any “breakaways.”
This allowed baseline times to be recorded for each rat. Preceding baseline training, one
magnetic “breakaway” rung was placed within the ladder and animals were timed once
again. In subsequent runs, animals anticipated the “breakaway” rung and tested the
stability of each as they crossed. Motion sensors to measure the animals’ speed collected
data. The rats were tested for two days during injections for baseline measurements, for
six days after injections with breakaways and again for six days without breakaways as a
recovery stage to gain their speed back.
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APPENDIX C
ADDITIONAL BIOCHEMICAL ASSAYS
Reactive Oxygen Species (ROS) Assay
Detection of reactive oxygen species (ROS) was conducted on fresh liver samples
of perfused rats. The liver was kept on ice and washed three times with sucrose buffer
[51.36 g sucrose, 6 mL of 1 M Tris-HCl, 600 µL of 100 mM EGTA and 10 µL of PMSF
in 600 mL of H2O, pH = 7.4]. Approximately 1 g of tissue was homogenized in 5
volumes of ice-cold sucrose buffer (5 mL per 1 g). The sample was then centrifuged at
3,500 r.p.m. for 10 minutes at 4 oC. The pellet containing cellular debris and nuclei was
discarded, and the supernatant was centrifuged again at 12,000 r.p.m. for 10 minutes on a
fixed rotor. The pellet was then re-suspended in 5 mL of sucrose buffer and centrifuged
once again at 12,000 r.p.m. for 10 minutes. The supernatant was discarded again and the
mitochondrial pellet was gently re-suspended in approximately 2 mL of sucrose buffer.
A Bradford assay was used to determine protein concentration of the
mitochondrial fraction of each sample so that 20 µg of protein could be added to each
well.

Each treatment was done in triplicate in a black, flat bottom 96 well plate.

Reaction buffer [500 µL of 1 M succinate and 125 µL of 1 M malate in 50 mL of PBS]
was added first, then the mitochondrial sample and some wells were pre-incubated with
WS-CoQ10 (50 µg/mL) for 5 minutes at 37oC. After incubation additional WS-CoQ10 (as
a control, optional) was added as well as paraquat treatment (100 µM). Amplex Red (10
µM) and horseradish peroxidase (HRP) were added then to all wells. The plate was
covered with aluminum foil and shaken briefly on a plate shaker.
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The plate was measured on a 96-well plate with excitation at 560 nm and emission
at 590 nm on Soft Max Pro software. Data was represented on Graph Pad Prism.

Cytokine Array
A cytokine array was used to assess the relative levels of multiple cytokines
expressed in treated rats. Tissue samples were homogenated according to the protocol
given by cytokine array kit from R&D Systems as was similar to the protocol above with
the exception of using PBS (pH = 7.6) as homgenization buffer with protease inhibitors (1
µM leupeptin, 1 µM pepstatin A and 10 µM PMSF) and 0.1% Triton X-100.
The Bradford assay was used to determine protein concentration and 100 µg from
each sample was incubated with the kit detection antibody cocktail for 1 hour on a rocker
at room temperature. The membranes were also incubated for 1 hour at room temperature
with blocking solution (Cytokine array kit R&D Systems).

The sample/detection

antibody cocktail mixture was then incubated with the membranes on a rocker overnight
at 4oC.
After overnight incubation, the membranes were washed with Wash buffer
(according to manufacturers manual, Cytokine array kit R&D Systems) for 30 minutes (3
x 10 minutes) and then incubated with Streptavidin-HRP for 30 minutes. They were
washed again for 30 minutes (3 x 10 minutes) and incubated with chemiluminescent
reagent in accordance with the manufacturer’s protocol. The membranes were imaged on
an Alpha Innotech Corporation Imaging System and qualified for relative levels of
fluorescence using ImageJ.
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APPENDIX D
ADDITIONAL EXPERIMENTAL DESIGN
Assessment of Paraquat Toxicity Following A Series of Injections
An experiment was conducted to determine if more/longer exposure to paraquat
increases dopaminergic neuronal cell loss in the substantia nigra. Nineteen rats were
divided into five groups of three (one group of four, Table A).

Animals were

administered intraperitoneal injections of paraquat (10 mg/kg) in series: 1, 2, 3, 4 or 5
injections, once every five days (Figure A). Animals were sacrificed one week after their
last injection and all brain tissue was used for immunochemistry. No biochemical assays
were conducted, and no behavioural experiments were conducted.
Table A: Groups for the assessment of paraquat toxicity following a series of
injections. Rat groupings based on type of injection and number of injections before
sacrifice.
Number of Injections

Treatment

Number of Rats

Sacrificed

1

Paraquat

3

1 week post-injection

2

Paraquat

3

1 week post last injection

3

Paraquat

3

1 week post last injection

4

Paraquat

3

1 week post last injection

5

Paraquat

3

1 week post last injection

5

Saline

4

1week post last injection
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Figure A: Timeline for assessment of paraquat toxicity following a series of
injections.
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APPENDIX E
STEREOLOGER SOFTWARE INSTRUCTIONS
Stereologer Study Information
Study name: Dopaminergic neuronal cell counting
PI: [Graduate student]
Species: Rat
Reference Space: Substantia nigra
Stereologer Case Information
Data collector: [person counting]
Date:
Group: [rat group, eg. Control, Paraquat-Injected, etc.]
Subject: [rat identification number]
Sampling Characteristics
Slab sampling Interval: 1
Total number of sections: [entire substantia nigra region]
Section sampling interval: 6 (approximately 10 sections counted in total)
Starting section: [first section to be counted]
Probe Parameters
Parameter

Probe

Feature

Number

Disector

Tyrosine hydroxylase positive neurons

Volume

Rotator Line IUR

Tyrosine hydroxylase mean cell volume

Volume

Region Point Count

Substantia nigra region volume
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Stereologer Counting
1.

2.

3.

4.

5.

6.
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1. Place brain tissue sample under 5x objective lens on bright-field microscope.
2. Outline the area of interest (substantia nigra, green) using the mouse.
3. Software places a grid overlaying the area of interest. Selected points within the
area of interest are green. Change this area by selecting or deselecting red/green
grid point using the mouse.
4. Change objective lens to 63x and select neurons that fall within the parameters of
the box. Green lines indication inclusions lines; neurons touching this line are
counted. Red lines are exclusions lines; neurons touching this line are not
counted.
5. Mean cell volume is calculated by indicating boundries of the cell body. To do
so, click on each line where the edge of the neuron touches the green lines.
6. Green circle represents the circumference of the cell body.
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